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Abstract 
Myocardial infarction (MI) occurs due to the complete occlusion of a coronary artery 
and is a leading cause of death, and a huge social and economic burden worldwide. Despite 
advances in treatment, patients still have a poor prognosis and there is a pressing need for 
strategies to improve cardiac repair post-MI. Stem cell factor (SCF), expressed by many cells 
and tissues including the myocardium, binds to its receptor, c-kit, and regulates the activity of 
c-kit-expressing cells. SCF has two isoforms: a soluble (S-SCF), and a membrane-associated 
isoform (M-SCF). M-SCF is more potent in supporting cell adhesion and survival. To date, 
little is known about the role of M-SCF in MI. This thesis investigated how M-SCF affects 
cardiac repair post-MI and the related mechanisms. To study the effects of M-SCF in cardiac 
repair post-MI, we generated a novel mouse model of inducible cardiac specific over-
expression of membrane-associated human SCF (hSCF). I utilized mouse models of MI and 
ischemia/reperfusion (I/R) induced through permanent and reversible ligation of the left 
coronary artery, respectively. Using these models, I investigated the effects of hSCF on 
cardiac function, cardiac repair, and related cellular and molecular mechanisms. I 
demonstrated for the first time that cardiomyocyte-specific overexpression of hSCF improves 
myocardial function and animal survival post-MI. These beneficial effects appear to have 
resulted from increases in c-kit+ stem cell retention, neovascularization, and decreases in 
myocardial apoptosis and cardiac remodeling. I also examined the cardioprotective effects of 
M-SCF in acute myocardial I/R injury. Overexpression of hSCF decreased myocardial 
apoptosis and infarct size via Akt-dependent signaling. Furthermore, I found that hSCF 
overexpression increases CD45-/c-kit+ cell activation following acute I/R through SCF/c-kit 
signaling. Finally, I examined the role of M-SCF in epicardial activation post-MI. I found 
 iii 
 
that overexpression of hSCF increased epicardial activation, enhanced epicardium-derived 
cell (EPDC) proliferation and migration via SCF/c-kit signaling, and promoted arteriogenesis 
post-MI. In conclusion, M-SCF improves cardiac repair and function through inhibiting 
myocardial apoptosis and cardiac remodeling, and by promoting neovascularization via c-kit+ 
stem cell recruitment and EPDC activation and migration. 
 
Keywords: Stem cell factor; Myocardial infarction; Cardiac remodeling ; Endothelial 
progenitor cells; Angiogenesis; Epicardium-derived cells ; Cardiac stem cells 
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1 CHAPTER 1 
Literature Review 
1.1 ISCHEMIC HEART DISEASE (IHD) 
IHD is a condition in which the heart muscle is damaged or works inefficiently 
due to an absence or relative deficiency of its blood supply. Most often caused by 
atherosclerosis, the clinical manifestation of IHD includes angina pectoris, acute 
myocardial infarction, chronic ischemic heart disease, and sudden death. IHD is the 
leading cause of death and a financial burden worldwide.1 For example, in the United 
States, IHD resulted in 445,687 deaths (about one of every five deaths) in 2005 and was 
reported to place a direct and indirect cost of $165.4 billion in 2009.1 Despite optimal 
treatment with existing drugs, the prognosis of IHD remains poor. Heart transplantation is 
the last but an effective option for end-stage IHD patients. The five-year survival rate of 
heart transplantation has achieved 70% in the United States.1 However, the limited 
donors for heart transplantation are not meeting the need of IHD patients. Thus, novel 
and effective treatments for IHD are in high demand. 
1.1.1 Physiology of the Heart 
The main function of the heart is to pump blood to meet the nutritional and 
metabolic requirements of the body. The muscular walls of the heart consist of three 
layers.2 The endocardium is the inner layer, consisting of endothelium and connective 
tissue, which covers the chambers and valves. The myocardium contains cardiomyocytes, 
fibroblasts, elastin and connective tissue, and the endomysium, which contains the 
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capillaries that supply the heart with oxygen. The outer layer of the heart wall is the 
epicardium, consisting of mesothelium and connective tissues. 
The heart pumps blood through two series circulations by coordinated actions of 
the atria and ventricles.3 Oxygenated blood from the lungs is received by the left atrium 
and is subsequently pumped into the aorta (systemic circulation) by the left ventricle 
(LV). The blood flows through arteries and capillaries to all tissues in the body to supply 
them with oxygen and nutrients. The deoxygenated blood returns to the right atrium of 
the heart from veins and is then pumped into the pulmonary circulation via the right 
ventricle to be re-oxygenated in the lungs. The heart generates continuous and sufficient 
blood circulation and can, by demand, increases its output. The coronary circulation is 
critical to maintain heart muscle function. Insufficient coronary perfusion caused by 
coronary artery narrowing or constriction results in cardiac ischemia leading to impaired 
cardiac function.4   
1.1.2 Myocardial Infarction (MI) 
Acute MI is an event which typically presents with a sudden onset of severe chest 
discomfort associated with elevations of ST segment on an electrocardiogram and 
increased enzyme levels in the blood such as creatine kinases, indicating cardiomyocyte 
death (heart muscle damage). MI is often due to the formation of thrombus (clot) in a 
coronary artery, which obstructs blood flow to the area of the myocardium supplied by 
the artery.5 Acute MI results in cardiomyocyte death starting within a few minutes after 
an ischemic attack. The loss of functional cardiomyocytes accompanied by inflammation 
in the first few days triggers a cascade of events resulting in the expansion of the 
infarcted area and early ventricular remodeling. At the same time, stem cells are activated 
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and recruited to the infarcted region.6 Following acute MI, re-establishing coronary blood 
flow by thrombolysis or primary angioplasty is widely used to salvage viable 
myocardium. However, the oxidative stress and abrupt metabolic changes immediately 
after reperfusion have been shown to initiate further cellular injury.7,8 Healing of the 
infarcted myocardium leads to scar formation and ventricular remodeling, which is 
characterized by ventricular enlargement, fibrosis and hypertrophic growth of the peri-
infarct and non-infarct myocardium. The remodeled LV causes cardiac dysfunction, 
clinical heart failure and increased mortality.5,9  
1.1.3 Heart Failure (HF) 
HF is a clinical syndrome characterized by impaired cardiac function and altered 
structure, leading to dyspnea and fatigue at rest or with exertion.10 Patients who survive a 
MI are at an increased risk of developing HF. The extent of LV systolic and diastolic 
dysfunction is associated with clinical symptoms and cardiovascular mortality. HF can be 
caused by the continuous abnormal loading conditions post-MI as a result of the infarct 
scar formation. The LV remodeling is a dynamic process that is driven by a number of 
factors.11 During cardiac remodeling post-MI, the LV becomes dilated, hypertrophic, and 
undergoes morphological and pathophysiological alterations. Pathologically, there is 
extensive fibrosis as well as disarray of abnormally structured myocardial cells. 
Furthermore, apoptosis becomes more active, resulting in additional loss of myocardial 
cells.12 It is the combination of these pathological changes that alters the structure of the 
heart and impairs cardiac function.   
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1.1.4 Current Treatment for MI and HF 
After an acute MI, patients often undergo revascularization in order to regain 
adequate blood supply to the myocardium. The two most widely employed treatments are 
angioplasty, in which the blocked artery is mechanically opened, and bypass surgery, in 
which vessels from elsewhere in the body are attached to bypass the blocked artery and 
re-establish blood flow. Also, MI patients receive pharmacological therapy to relieve 
angina, prevent thrombus propagation and to stabilize the “vulnerable” plaque.13 Anti-
anginal drugs, which affect the balance between oxygen supply and demand, include 
nitroglycerin, β-adrenergic blockers, and calcium channel blockers. To reduce thrombus 
formation, anti-platelet and antithrombotic treatments are also recommended, unless 
contraindicated. Antiplatelet agents include aspirin, thienopyridines, and glycoprotein 
IIb/IIIa inhibitors. Commonly used antithrombotic agents include unfractionated heparin, 
low-molecular-weight heparin, fondaparinux, and bivalirudin. Furthermore, statin therapy 
promotes plaque stabilization and restores endothelial function, and has been shown to 
reduce the incidence of myocardial infarction, recurrent ischemia and mortality. 
HF is a chronic disease that requires lifelong management including 
pharmacological therapy and lifestyle modification.14 Angiotensin-converting-enzyme 
(ACE) inhibitors are now considered a first-choice in HF drug therapy. ACE inhibitors 
limit the formation of angiotensin II resulting in vessel dilation as well as the prevention 
of cardiac hypertrophy, fibrosis and decreased afterload and preload of the heart. 
Angiotensin II receptor blockers, which have similar effects, can be used as an alternative 
for patient who are unable to tolerant ACE inhibitors. Diuretics are prescribed for patients 
who have volume overload in the body and swelling of the tissues. Digoxin increases the 
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force of cardiac contractions and relieves heart failure symptoms, especially when the 
patient is not responding to ACE inhibitors and diuretics. Beta-blockers are prescribed to 
reduce heart rate and lower blood pressure. They also inhibit ventricular remodeling and 
reduce the risk of arrhythmias and sudden death.15 Lifestyle modifications include losing 
weight, quitting smoking, avoiding alcohol and caffeine, eating a low-saturated-fat low-
sodium diet, exercising and reducing stress, all of which have been shown to alleviate 
symptoms, slow disease progression and improve quality of life. 
In spite of significant progress in clinical treatment, the prognosis of HF remains 
poor. At present there is no cure for patients with end-stage HF except heart 
transplantation. Drug treatment can attenuate myocardial remodeling and improve 
survival, but does not reduce the size of the scar. Unfortunately, angioplasty or bypass 
surgery does not reverse the damage induced by MI. LV assist devices can prolong 
patient lives only for a few years.16,17 On the other hand, although the survival rate after 
heart transplantation is excellent, the source of transplantable donor hearts is scarce. 
Therefore, there is a need for developing new and effective therapies to treat patients with 
HF post-MI. Approaches to limit cardiomyocyte loss, rebuild the coronary microvascular 
network and impede cardiac remodeling have been widely investigated to improve 
cardiac function post-MI.   
1.2 NEW APPROACHES TO TREAT IHD 
The fundamental pathophysiological changes post-MI include cardiac cell death, 
pro-inflammatory response, dynamic change of extracellular matrix, cardiac fibrosis, 
cardiac neovascularization, cardiac remodeling and very limited regeneration of cardiac 
myocytes, which are potential therapeutic targets for developing new treatments for IHD. 
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Approaches to decrease myocardial cell death, enhance cardiac regeneration and impair 
cardiac remodeling have shown promising beneficial outcomes in animal models.  
1.2.1 Inhibition of Myocardial Apoptosis 
An extensive loss of cardiomyocytes is associated with IHD.  During acute MI, 
cell death is seen at the earliest onset of the disease.18 It is widely accepted that both 
necrotic and apoptotic cell death are involved in the loss of cardiomyocytes in MI and 
during ischemia/reperfusion (I/R) injury.19,20 In human acute MI, ischemic regions of the 
heart contain between 0.8% and 12% apoptotic cardiac myocytes compared to 
approximate 0.005% apoptotic cells in non-ischemic regions.21 Apoptosis is a finely 
regulated mode of cell death initiated by an intracellular program,22 which results in a 
loss of cells without inflammation. Apoptotic cell death is of great interest to the medical 
community because it can be effectively manipulated by pharmacological 
interventions.20,23  Inhibition of apoptotic cell death has beneficial effects in HF. For 
example, excessive stimulation of the β1 adrenergic receptor (β1AR), such as that seen 
during HF, is known to induce myocardial apoptosis.24  Beneficial effects of β receptor 
blockade in patients with HF may partially be due to an inhibition of β1AR-induced 
apoptosis.25 A recent study by Chandrashekhar et al. demonstrated that inhibition of 
apoptosis improves cardiac function of rats after MI.26  In this study, reduction of 
apoptosis via caspase-3 inhibition was associated with improved systolic function, the 
preservation of myocardial contractile proteins and the attenuation of ventricular 
remodeling. A return of blood flow after ischemia through reperfusion of the tissue can 
also cause “reperfusion injury”. Reperfusion is known to accelerate cardiomyocyte 
apoptosis following myocardial ischemia.27 Interventions which suppress myocardial 
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apoptosis during I/R injury have been demonstrated to decrease infarct size and improve 
cardiac function.28-30 Additionally, activation of pro-survival kinases including Akt has 
been shown to provide significant anti-apoptotic effects in MI and I/R. 
1.2.2 Activation of Akt Signaling  
Injury due to myocardial I/R results in loss of functional cardiomyocytes and 
inflammatory responses which lead to stress signaling and oxidative damage. Since 
signaling molecules and pathways are potential therapeutic targets, it is important to 
unravel the relevant signaling pathways involved in cardiac injury. Numerous studies on 
acute cardio-protective signaling pathways activated by pre- and post-conditioning have 
shown that phosphoinositide-3-kinase (PI3K)/Akt,31,32 glycogen synthase kinase-3β 
(GSK-3β),33 endothelial nitric oxide synthase (eNOS),34,35 extracellular signal-regulated 
kinase (ERK),36,37 and p38 mitogen-activated protein kinase (MAPK) 38,39 are involved.40 
Collectively, these pro-survival pathways are known as the reperfusion injury salvage 
kinase (RISK) pathway.40 The ability of Akt to phosphorylate multiple substrates 
positions it as a central regulator in the RISK pathway.41 Akt is a 57-kD protein-
serine/threonine kinase. The activation of Akt requires both translocation and 
phosphorylation. Akt is recruited to the plasma membrane by PIP3, the phosphorylation 
product of PI3K, and phosphorylated by phosphoinositide-dependent kinase 1(PDK1) to 
achieve full activation.42 The substrates of Akt include eNOS, GSK-3β, Bcl-xl/Bcl-2–
associated death promoter (BAD), caspase-9, Ikkα, mammalian target of rapamycin 
(mTOR) and forkhead transcription factor (Figure 1.1). Studies from our lab 
demonstrated that activation of Akt by erythropoietin (EPO) treatment reduces infarct  
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Figure 1.1 Cardioprotective PI3K/Akt signaling pathways in ischemia/reperfusion 
(I/R).  
In response to I/R injury, increased myocardial expression of cardioprotective growth 
factors activate PI3K/Akt signaling pathways. Through phosphorylation by PI3K, Akt 
either inhibits or activates its downstream substrates in the cytoplasm and nucleus to 
prevent apoptosis and promote cell survival. In the cytoplasm, Akt phosphorylates BAD 
and caspase-9 to directly inhibit apoptosis. Phosphorylation of eNOS by Akt results in 
enhanced cell survival. In the nucleus, Akt inhibits forkhead transcription factors and 
activates nuclear factor κB (NF-κB) to induce expression of anti-apoptotic factors and 
protective growth factors.  
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size and protects against myocardial apoptosis after I/R by phosphorylation of eNOS via 
the PI3K/Akt signaling pathway.34 Akt can also directly inhibit caspase-mediated cell 
death through the phosphorylation of BAD, releasing Bcl-2 family members to maintain 
mitochondrial permeability 43 and the phosphorylation of caspase-9.44 Additionally, Akt 
can protect against cardiomyocyte apoptosis by regulating gene expression of Glut-1, 
vascular endothelial growth factor (VEGF), Bcl-2 and forkhead transcription factors.45 
Furthermore, Akt plays a critical role in endothelial homeostasis and angiogenesis by 
maintaining endothelial cell viability, regulating migration and promoting the homing of 
endothelial progenitor cells (EPCs) in the ischemic heart after I/R.46,47 
1.2.3 Improvement of Cardiac Repair post-MI 
The endogenous healing process post-MI is manifested by increased matrix 
synthesis, fibroblast proliferation and the release of pro-fibrotic cytokines, resulting in 
scar formation. The infarct size, which is critical to disease progression and prognosis, is 
determined by the area of coronary artery occlusion and dynamic changes during the 
remodeling process.48 The ideal cardiac repair would include the complete regeneration 
of the myocardium and neovascularization, which has been observed in Zebra fish,49 the 
adult newt,50 and the neonatal mouse.51 However, the ability to regenerate myocardial 
tissue follow injury is diminished in the adult mammals.51    
1.2.3.1 Neovascularization post-MI 
Effective cardiac repair post-MI most likely depends on the blood supply in the 
border zone and the infarcted area, which not only supports the surviving 
cardiomyocytes, but also promotes the establishment of myofibroblast-rich granulation 
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tissues.52 Neovascularization can be achieved by a number of different mechanisms 
including sprouting of capillaries from pre-existing endothelial cells (angiogenesis), in 
situ formation of blood vessels from EPCs or angioblasts (vasculogenesis) and by 
increasing in the size and caliber of pre-existing arteriolar collaterals (arteriogenesis).53 
Tissue hypoxia stimulates neovascularization by up-regulating pro-angiogenic factors 
partially via the transcription factor, hypoxia inducible factor.54 Pro-angiogenic growth 
factors such as VEGF and basic fibroblast growth factor (bFGF) are increased in the 
ischemic myocardium.55-57 VEGF stimulates endothelial cell proliferation and EPC 
mobilization from the bone marrow,58,59 and contributes to both angiogenesis and 
vasculogenesis. bFGF is a potent mitogen of endothelial cells and acts as a chemotactic 
factor promoting endothelial cell migration during angiogenesis.60 Studies have shown 
that intracoronary artery administration of VEGF and bFGF post-MI in animal models 
enhances vessel collateral formation and improves cardiac function. Despite a potential 
risk of growth and destabilization of atherosclerotic plaques associated with pro-
angiogenic factor treatment,61,62 protein-based angiogenic clinical trials in IHD using 
VEGF or bFGF have been carried out worldwide. The results of recombinant human 
VEGF or bFGF delivery to patients with coronary artery disease were disappointing, 
showing no improvement compared to placebo.63,64 However, beneficial clinical 
outcomes were reported in some of the clinical trials using adenoviral VEGF gene 
therapy.65 Thus, further development of gene delivery techniques and optimization of 
therapeutic indications are required to translate the promising outcomes obtained from 
animal studies using pro-angiogenic growth factors into clinical success. 
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An alternate approach for angiogenic therapy is stem cell treatment including 
stem cell transplantation or manipulating stem cell recruitment and retention. Since the 
early 2000’s, efforts to repair the infarcted heart with newly generated cardiomyocytes 
from bone marrow-derived stem cells have evolved and boosted intensive worldwide 
research on stem cell therapy post-MI.66 Although initial animal studies claimed 
cardiomyocyte trans-differentiation from bone marrow stem cells post-MI,67,68 many later 
studies were not able to repeat this observation. The incidence of cardiomyocyte trans-
differentiation from bone marrow stem cells, if it occurs at all, is far too low to 
effectively repair the infarcted heart.69-71 The current understanding is that the protective 
effects observed in most bone marrow-derived stem cell treatments post-MI in animal 
studies are mediated by the paracrine effects leading to decreased apoptosis, increased 
angiogenesis or vasculogenesis, modulation of local inflammatory milieu and decreased 
cardiac remodeling.72 Mesenchymal stem cells also have the ability to differentiate into 
perivascular cells that stabilize nascent blood vessels and respond to vasoactive stimuli.73 
Thus, the enhanced recruitment of different types of stem cells and progenitors may work 
together to create a more functional microcirculation network, leading to more efficient 
cardiac repair post-MI. However, despite the success in enhancing cardiac repair post-MI 
in animal models, treatment with bone marrow or peripheral blood derived stem cells had 
only minor or no functional improvements in clinical trials.74-76 The unsatisfactory results 
from these clinical trials have revealed many critical questions of stem cell therapy in MI. 
For example, which stem cell type has the best therapeutic effects? How might it be 
possible to retain functional stem cells in the infarcted heart? Answers to these questions 
may help to improve stem cell therapy in patients with MI.  
13 
 
1.2.3.2 Endogenous Cardiomyocyte Regeneration post-MI 
The general belief that the heart is a completely post-mitotic organ has been 
challenged by the recent evidence, which suggests the possibility of cardiomyocyte 
regeneration in cardiac homeostasis and pathology.77 Myocyte death occurs in the normal 
heart and the frequency of cell death increases with IHD.77,78 In the rat heart, it has been 
estimated that approximately 94,200 myocytes die every 24 hours under normal 
physiological condition, which in turn would be expected to lead to the loss of all 
cardiomyocytes within 5 months.79,80 In order to maintain normal heart homeostasis, a 
balance between cell death and regeneration must be achieved.  Recently 2 independent 
studies have measured cardiomyocyte DNA synthesis in human hearts based on 
retrospective 14C birth dating of cells 81 and incorporation of radiosensitizer 
iododeoxyuridine,82 respectively. Although the measured myocyte turnover rates differ 
between them, both studies have provided direct evidence of the regeneration of 
cardiomyocytes and the plasticity of the adult human heart. Furthermore, the observation 
of the host Y-chromosome in sex-mismatched female donor hearts strongly suggests the 
regeneration of myocytes and vascular structures from the host.83 Despite the intense 
debate on the cellular sources of newly generated myocytes, it is now widely accepted 
that the adult heart has some, albeit limited, endogenous repair ability.84 A recent study 
using genetic fate mapping to distinguish cardiomyocyte renewal from pre-existing 
cardiomyocytes or non-cardiomyocyte sources has revealed the contribution of non-
cardiomyocyte cells in myocyte renewal in the remote area post-MI in mice.85 However, 
the stem/progenitor cell source of the regenerated myocytes and the underlying 
mechanisms regulating myocardial renewal remains to be investigated.     
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1.3 STEM CELLS IN CARDIAC REPAIR POST-MI 
Stem cells are defined by their unique properties: self-renewal capacity and the 
potential to differentiate into one or more specialized cell types.86 Stem cells have the 
ability to undergo asymmetric and symmetric cell division. Asymmetric cell division 
gives rise to two daughter cells that have different fates, one maintaining the stem cell 
population and the other generating differentiated cells.87 Stem cells can be classified into 
3 major categories: embryonic, induced pluripotent and adult stem cells.74,88,89 Both 
embryonic and induced pluripotent stem cells are pluripotent and can generate any cell 
type in the body. However, they present a high risk of teratoma formation, which makes 
them unacceptable for clinical treatment at this time. Interestingly, small populations of 
clonogenic, self-renewing, and multipotent cells have been found in different adult 
tissues including bone marrow, vascular walls, adipose tissues, skeletal muscles, heart 
and brain as well as the epithelium of the lung, liver, pancreas, digestive tract, skin, 
limbus, retina, breast, ovaries, prostate and testis.90,91 These multipotent stem cells, 
referred to as adult stem cells, have the potential to differentiate into mature cell lineages 
in tissues from which they originate and contribute to postnatal organ homeostasis. 
Furthermore, bone marrow-derived stem/progenitor cells may also migrate to distant 
peripheral sites after intense injury and contribute to tissue repair.91,92 Adult stem cells 
reside in a specific cellular niche, which ensures a balance between the maintenance of 
the stem cell pool and the production of daughter progenitor cells engaged in lineage 
differentiation.93 The in vivo stimulation of adult stem cells or the use of their ex vivo 
expanded and differentiated progenies is emerging as a promising approach for cell 
replacement-based therapies. Interestingly, several types of adult stem cells, including 
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bone marrow-derived stem cells, resident cardiac stem cells and epicardium-derived cells 
have shown cardiac myogenic and vasculogenic potential, which make them favorable 
candidates for cardiac repair post-MI.77,94 (Figure 1.2) 
1.3.1 Bone Marrow-derived Stem Cells (BMSC) 
Bone marrow is a rich and readily accessible source of adult stem cells including 
hematopoietic stem cells (HSCs), multipotent mesenchymal stromal cells (MSCs) and 
EPCs. The potential of HSCs to give rise to myogenic lineages has been intensively 
investigated. In vitro, HSCs have been shown to transdifferentiate into cardiac myogenic 
cells in co-cultures with neonatal cardiomyocytes,95 or by treatment with VEGF and 
bFGF 96 or transforming growth factor β (TGFβ).97 However, cardiac regeneration by 
stem cell transplantation using Lin-c-kit+ HSCs post-MI remains highly controversial. 
Evidence of the cardiac regeneration potential of BMSCs in vivo was initially determined 
by gender mismatch heart transplantation studies in which Y chromosome 
cardiomyocytes and endothelial cells were detected at a very low level in male recipients 
receiving female donor hearts.83,98 In 2001, Orlic et al. reported a substantial engraftment 
of the transplanted Lin-c-kit+ HSCs post-MI and significant regeneration of 
cardiomyocytes and vascular structure from the HSCs in mice.67 However, 3 subsequent 
studies in 2004 failed to observe any cardiomyocyte regeneration from the transplanted 
HSCs using similar experimental approaches.69,99,100 Nevertheless, the beneficial effects 
of transplanted Lin-c-kit+ HSCs on cardiac function have been confirmed by a number of 
studies.101-103 The improved cardiac function in such cases may mainly result from  
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Figure 1.2  Potential cell sources for cardiogenesis post-MI.  
Cell therapy using bone marrow-derived stem cells (BMSCs), cardiac stem cells (CSCs)  
and epicardium-derived cells (EPDCs) has been shown to inhibit cardiomyocyte cell 
death and cardiac remodeling, and promote regeneration of blood vessels and 
cardiomyocytes post-MI. 
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trophic factors released from the HSCs, which are referred to as paracrine effects.104  
MSCs were originally identified as a small subpopulation of bone marrow cells 
which have the ability to differentiate into tissue types of mesodermal origin, such as 
chondrocytes, adipocytes and osteocytes.105  MSCs have been successfully isolated from 
various non-marrow tissues such as umbilical cord blood 106 and adipose tissue.107 DNA 
demethylating agents, such as 5-azacytidine, have been shown to induce MSC 
transdifferentiation into cardiomyocytes in vitro.108,109 Cell therapy using MSCs has been 
well-documented to improve cardiac performance and promote neovascularization, which 
are now considered mostly due to the paracrine effects instead of cardiomyocyte 
regeneration.110,111 There are several advantages of using MSCs in cell therapy in IHD 
compared to HSCs. First, they can be easily cultured and expanded in vitro to the large 
population needed for transplantation. Second, they can be engineered in vitro to achieve 
specific characteristics. Third, they have been shown to contribute to both myocardial and 
vascular repair post-MI. Last, they have immunological privilege by regulating immune 
cell activity, which makes MSCs a potential candidate for allogenetic treatment.112  
To date, the meta-analysis of numerous clinical trials applying autologous 
BMSCs to IHD patients has confirmed the safety of this treatment and revealed a 
moderate improvement in physiological and anatomical cardiac parameters above and 
beyond conventional therapy.113,114 However, the 2 recent trails studying the effects of 
bone marrow-derived mononuclear cells (MNCs) in acute MI (TIME) 76 or bone marrow 
derived MSCs in chronic MI (CCTRN) 75 showed no improvement in cardiac 
performance. Although better characterization and understanding of different 
subpopulations of BMSCs, and optimal time and conditions for their transplantation may 
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be needed in order to achieve the best outcome for BMSCs stem cell therapy in IHD 
patients. The lack of benefit of bone marrow-derived MNCs therapy suggests that it is not 
an optimal stem cell type for IHD treatment.  
Endothelial progenitor cells (EPCs) are a rare population of cells that circulate in 
the blood and have the ability to differentiate into endothelial cells and promote 
neovascularization. Bone marrow is the major source of adult EPCs. EPCs share many 
markers with HSCs, which makes it difficult to identify EPCs strictly by specific marker 
expression. The most widely used markers for EPCs include c-kit, CD34, CD133 and 
vascular endothelial growth factor receptor 2 (VEGFR2). In vitro culture of mononuclear 
bone marrow cells yields 2 types of EPCs: early outgrowth and late outgrowth EPCs.115 
The early outgrowth EPCs have been shown to be of hematopoietic origin and potently 
induce angiogenesis without incorporating in blood vessels, while the late outgrowth 
EPCs are considered real EPCs which can be clonally expanded and give rise to 
endothelial cells. During neovascularization, EPCs are released from bone marrow to the 
peripheral circulation and mobilize to the target tissue. Mobilization of EPCs after 
cardiac ischemia is also observed in patients after acute MI.116 Animal studies have 
demonstrated that EPC transplantation or treatment with agents that enhance EPC 
mobilization and recruitment post-MI improves cardiac function and reduces cardiac 
remodeling via angiogenesis and vasculogenesis.52,117-120 
1.3.2 Cardiac Stem Cells (CSCs) 
The adult heart has traditionally been considered as a post-mitotic organ with 
limited ability to regenerate. Recent studies have challenged this dogma and shown that 
resident cardiac stem cells exist in the adult heart.121-123 Although the number of CSCs is 
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low in the adult heart, they are committed to generate cardiomyocytes and their numbers 
can be expanded ex vivo for therapeutic purposes.66 Different approaches are employed to 
identify the resident CSCs, including detection of specific surface markers such as c-kit, 
and assessment of their unique physiological properties such as the ability to form 
cardiospheres in culture or to efflux Hoechst 33342 dye (side population progenitors).  
CSCs expressing c-kit have been intensively studied. They are found in niches in 
the normal heart at a frequency of 1 out of approximately 30,000 cells.122,124-126 In 
culture, c-kit+ CSCs are multi-potent, giving rise to cardiomyocytes, smooth muscle cells 
and endothelial cells.122 Moreover, transplantation of c-kit+ CSCs into the infarcted 
myocardium induces cardiomyocyte regeneration post-MI.124,127 However, negative 
results were reported in studies using cell fate-mapping strategies. In this regard, no 
evidence of cardiomyocyte differentiation from c-kit+ cells has been found in the adult 
mouse heart.128,129 Despite this controversy, a phase I clinical trial has been initiated to 
study the safety and feasibility of autologous c-kit+ CSCs in patients undergoing coronary 
bypass surgery (ClinicalTrials.gov Identifier: NCT00474461). Cells were isolated and 
cultured from each patient’s right atrial appendage, followed by immunomagnetic sorting 
with anti-c-kit antibody-coated microbeads.130 Significant improvement in LV ejection 
fraction (41.2% vs 27.5%) and viable cardiac tissue mass was reported 12 months after c-
kit+ CSC infusion in 20 patients,130 which so far is the best clinical outcome achieved in 
all stem cell therapy trials in coronary heart disease. However, global percentage change 
of ventricle infarct size, which may indicate the myocardial regeneration, were not 
reported.130 
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Cardiosphere-derived cells (CDCs) are also CSCs identified through their ability 
to migrate from cultured cardiac tissues and form floating spheres. CDCs are isolated 
from minimally invasive percutaneous endomyocardial biopsies from the adult human 
heart 131 and the myocardium from other species (mice, rats and pigs).132,133 The CDCs 
are a mixture of c-kit+ cells and supporting endothelial and mesenchymal cells that can be 
amplified in culture and grown to millions in a few weeks.133 Intracoronary delivery of 
CDCs has been shown to improve cardiac repair and function in animal MI models.131,134 
A phase I clinical trial was carried out to study the safety and efficacy of CDCs in 
patients with a recent MI (ClinicalTrials.gov Identifier: NCT00893360). Reduction in 
scar mass, increased viable heart mass and regional contractility was observed in 17 
patients with MI, 6 months after CDCs treatment, while no significant changes in ejection 
fraction, end-diastolic and end-systolic volume were found.135 Cell therapies with 
autologous c-kit+ CSCs or CDCs after MI have been shown to be safe and beneficial, and 
warrant phase 2 studies to test their efficacy.        
Several other populations of CSCs are also under investigation. Stem cell antigen 
1 (Sca-1) positive CSCs express early cardiac transcription factors including GATA4 and 
MEF2. When treated with 5-azacytidine or oxytocin, Sca1+ CSCs can differentiate into 
spontaneously beating cardiomyocytes in vitro.136 Intravenous administrations of Sca1+ 
CSCs to mice following myocardial ischemia/reperfusion showed 50% fusion with host 
cardiomyocytes.137 Moreover, transplantation of Sca-1+CD31- CSCs in the infarcted 
mouse heart improved cardiac function and angiogenesis through paracrine effects.138 
Further studies are needed to determine the clonogenic and self-renewal potential of Sca-
1+ CSCs and their capacity in cardiomyocyte differentiation. Another population of 
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multipotent CSCs marked by the LIM-homeodomain transcription factor islet-1 (Isl-1) 
has been shown to give rise to cardiomyocytes, endothelial and smooth muscle cells both 
in vitro and in vivo. The Isl-1+ CSCs are mainly located in the outflow tract and right 
atrium of fetal or very young postnatal hearts and are negative for c-kit and Sca-1.139 The 
fact that Isl-1+ CSCs exist in very low numbers in the adult heart limits their therapeutic 
potential. Furthermore, the property of cardiac progenitor cells to expel toxic molecules 
through an ATP-binding cassette transporter 140 is also employed to define a pool of 
CSCs. They are termed cardiac side population cells (CSPs)  because after exposure to 
the DNA-binding dye, Hoechst 33342, they can clear the fluorochrome and appear on the 
side of the flow cytometry profile.141 CSPs are positive for Sca-1 and negative for c-kit.142 
CD31-Sca-1+ CSPs form colonies in vitro and differentiate into cardiomyocytes.142,143 
When transplanted into animals with MI, CSPs can migrate to the injured myocardium 
and differentiate into cardiomyocyte- and endothelial-like cells.144,145 
To date, whether the resident CSCs identified by different methods represent 
distinct populations of stem/progenitor cells or they are actually the same line of stem 
cells at different stage of maturation remains unknown. Exploitation of CSCs in stem cell 
therapy for IHD is certainly an exciting and promising strategy. However, further 
investigations of the endogenous regulatory mechanisms of CSCs survival, proliferation 
and differentiation under physiological or pathological conditions are definitely needed 
before stem cell therapy can be safely and effectively applied to IHD patients.   
1.3.3 Epicardium-derived Cells (EPDCs) 
During embryonic cardiomorphogenesis, cells from the proepicardial organ 
migrate to the myocardial surface after looping of the primitive heart tube to form the 
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epicardium.146 A fraction of these cells undergo epithelial to mesenchymal transition 
(EMT) and invade the myocardium to give rise to coronary smooth muscle cells, 
subendocardial and atrioventricular cushion mesenchymal cells and adventitial, 
perivascular and cardiac interstitial fibroblasts.147-150 These cells are referred to as 
EPDCs. Besides their structural contribution, an important modulatory role of EDPCs in 
the formation of the compact myocardium and coronary vessels, and differentiation of 
Purkinje fibers has been proposed.151-153 During embryonic heart development, Wilms 
tumor 1 (Wt1) protein is expressed in EPDCs and is involved in the regulation of EMT. 
However, expression of Wt1 is lost in fully differentiated EPDCs.153-156 Recently, the 
adult epicardium, which has been considered to be terminally differentiated, was found to 
be a potential source of vascular progenitors after appropriate stimulation. Riley et al. 
demonstrated a significant outgrowth from adult mouse epicardial explants after 
thymosin β4 stimulation. These EPDCs were able to migrate and differentiate into 
fibroblasts, smooth muscle and endothelial cells.157 Moreover, upregulation of 
cardiomyocyte prokineticin receptor-1signaling has been shown to be able to trigger adult 
mouse EPDCs migration and differentiation into endothelial and smooth muscle cells.158 
Similar findings were observed in adult human EPDCs which differentiated into smooth 
muscle cells after treatment with TGF-β or bone morphogenetic protein-2 (BMP-2). 
Interestingly, expression of the cardiac marker genes GATA4 and cardiac troponin T was 
also detected in cultured human adult EPDCs.159 The ability of the adult epicardium to 
restore multi-potency makes adult EPDCs a novel promising therapeutic candidate in 
ischemic heart disease.  
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Several studies have investigated the potential of adult EPDCs in cardiac repair 
post-MI. Transplantation of human adult EPDCs into the ischemic myocardium 
preserved cardiac function and attenuated ventricular remodeling via enhanced 
vascularization in mice. The engrafted EPDCs were found to express endothelial marker 
von Willebrand factor (vWF) and the smooth muscle marker α-smooth muscle actin (α-
SMA) 2 weeks post-MI, suggesting neovascularization.160 However, the transplanted 
EPDCs did not express cardiomyocyte markers such as atrial natriuretic peptide, 
sarcomeric myosin or cardiac troponin I.160 Furthermore, c-kit+ and CD34+ cells were 
detected in adult mouse epicardium and the number of epicardial c-kit+ cells significantly 
increased post-MI. After fresh isolation, these cells expressed cardiac transcription 
factors and acquired an endothelial phenotype in vitro.161 Although, in that study, the 
authors found increased c-kit+/GATA4+, c-kit+/ vWF + and c-kit+/smooth muscle actin+ 
cells in the subepicardial space 3 days post-MI, there was no direct proof that these cells 
were EPDCs. Interestingly, some of the EPDCs traced by lentiviral green fluorescent 
protein (GFP) were found to express α-sarcomeric actin (a cardiac muscle actin) post-MI, 
but the authors did not quantify the incidence of this transdifferentiation.161 Following 
MI, the adult epicardium is reactivated 161 and may have the potential to repair the 
infarcted myocardium.162 The ability of the adult epicardium to regain progenitor 
potential is defined as epicardial activation. Thus, understanding the role of the 
epicardium and factors that regulate its activation will be critical to developing therapies 
to enhance endogenous cardiac repair post-MI. 
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1.4 STEM CELL FACTOR (SCF) 
SCF, also known as Steel factor, mast cell growth factor, or c-kit ligand, binds to 
c-kit and promotes survival, proliferation, mobilization, and adhesion of all c-kit-
expressing cells. c-kit is a tyrosine kinase receptor expressed in stem cells and progenitors 
including BMSCs, CSCs and some EPDCs 122,163,164 while SCF is ubiquitously expressed 
as a glycosylated transmembrane protein widely throughout the body by stromal cells,165 
fibroblasts, endothelial cells and the myocardium. Alternative mRNA splicing leads to 
two isoforms of SCF: soluble (S-SCF) and membrane-associated (M-SCF), which differ 
in the absence or presence of a particular proteolytic cleavage site encoded by exon 6.166 
S- and M-SCF have distinct but overlapping roles. M-SCF is the dominant isoform in 
vivo and induces more persistence and long-term support of target cell survival via 
juxtacrine, but may be less effective in stimulating growth.166-168  
1.4.1 SCF Biology 
In 1990, SCF was initially found to be a growth factor that can stimulate both 
primitive and mature hematopoietic progenitor cells.169 Then it was identified to be the 
product of Steel (Sl) gene in mouse chromosome 12, between 12q14.3 and 12qter in 
human and the ligand for the c-kit tyrosine kinase receptor.170 The protein sequence is 
highly conserved, and there is more than 80% amino acid homology between mouse and 
human.171  Mutation of Sl locus results in alterations of coat color, sterility, anemia and 
lack of mast cells due to impaired development of hematopoietic cells, germ cells and 
neural crest derivatives such as melanocytes caused by the altered microenvironment.172 
Sl/Sl homozygotes are deficient in germ cells, devoid of coat pigment and die perinatally 
from macrocytic anemia.172 SCF has a major role in hematopoiesis, spermatogenesis and 
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melanogenesis, and works in synergy with other growth factors. In vitro, SCF treatment 
induces survival, proliferation and migration of HSCs, melanoblasts and primordial germ 
cells.173 In vivo, recombinant S-SCF elicits a multilineage response in peripheral counts 
and increases bone marrow cell mass, which protects against lethal irradiation by 
accelerating hematopoietic recovery.174-176  
S- and M-SCF result from pre -translational processing of primary SCF mRNA 
transcripts. The full-length mouse SCF consists of 248 amino acids (SCF248) with an 
extracellular domain, a membrane-spanning region and a short cytoplasmic tail. 
Proteolytic cleavage at Ala 165 releases a 164-amino-acid biological active growth 
factor, S-SCF. Another mRNA transcript produced by alternative splicing leads to the 
production of the 220 amino acid M-SCF (SCF220), which lacks the main cleavage site 
Ala 165 encoded by exon 6. Compared to full-length SCF248, the release of S-SCF from 
SCF220 is less efficient in COS cells 168 and mouse stromal cells.177 As suggested by 
protease inhibitor profiles and sequence analysis, a distinct protease on a secondary 
cleavage site may be involved in producing the S-SCF from M-SCF.168,178 To this end, 
Majumdar et al identified the second cleavage site in mouse M-SCF encoded by exon 
7.177 Interestingly, a species specific difference of the secondary proteolytic cleavage was 
demonstrated in M-SCF, showing that 95% human M-SCF remained membrane-bounded 
while 20% of mouse M-SCF was cleaved into S-SCF after glycosidase overnight 
digestion in vitro.177 The protease involved in natural shedding of S-SCF remains 
unknown, but it may be a metalloprotease.179 In vivo, metalloprotease-9 has been shown 
to be important in S-SCF release from HSCs, but the cleavage domain was not 
identified.180 Activation of protein kinase C (PKC) signaling by phorbol 12-myristate 13-
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acetate (PMA) is able to increase the shedding in COS-1 cells transfected with mouse M-
SCF.168 The biological activity of the S-SCF released from M-SCF is similar to that of 
the proteolytic product of the full length SCF.  
The expression patterns of full length SCF and M-SCF are also different. Full 
length SCF is expressed widely in most organs and tissues while M-SCF is expressed in a 
tissue-specific manner. It can be easily detected in heart, lung, spleen, bone marrow and 
testis but is barely seen in brain.168 This suggests that M-SCF may play a different role 
from the S-SCF in different organs.  In this regard, mice with the Sl/Sld mutation (deletion 
of the SCF tans-membrane and cytoplasmic domain) exhibit abnormal phenotypes 
including anemia, sterility and white spotting.172  When M-SCF was expressed in Sl/Sld 
mice the anemia, bone marrow hypocellularity and runting were improved.181 On the 
other hand, M-SCF may substitute for full-length SCF in most situations except for mast 
cell production and regeneration of hematopoietic tissue after radiation.182 The distinct 
but overlapping effects of the 2 isoforms are based on their natural characteristics 
(Figure 1.3). S-SCF is a diffusible factor that acts on target cells over short or long 
distances (endocrine and paracrine). The normal human serum level of S-SCF is about 
3.3 ng/mL 183 and can be altered by different disease conditions such as cancer184 and 
Alzheimer’s disease.185 Moreover, S-SCF may also be associated with or sequestered in 
the extracellular matrix and thus function in a manner similar to M-SCF. M-SCF mainly 
mediates cell-cell interactions and adhesion, during which it may be able to act at a 
sustained high concentration as a localized signal to target cells (juxtacrine). On the other 
hand, the intercellular signaling induced by S-SCF may be relatively low and variable.  
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Figure 1.3 Illustration of soluble (S-SCF) and membrane-associated SCF (M-SCF). 
 S-SCF is released from the full-length SCF after proteolytic cleavage at the main 
cleavage site encoded by exon 6. It can act on c-kit expressing cells nearby (paracrine) or 
at long distant (endocrine). M-SCF mainly remains membrane bounded and is involved 
in adhesion and activation of c-kit expressing cells by cell-cell interaction (juxtacrine). 
Full length SCF can also have juxtacrine effects before the S-SCF is released. 
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Thus, it is not surprising that M-SCF provides greater survival and proliferation signals 
compared to the soluble isoform.181,186 It also appears that the 2 isoforms of SCF have 
different signaling pathways for their biological activities. For example, although both S-
SCF and M-SCF can induce proliferation of erythroid progenitors via activation of p38 
and ERK pathways, M-SCF-induced signaling is more sensitive to ERK inhibition while 
p38 inhibition works better on S-SCF.186 Thus, through expression of different SCF 
isoforms, stromal cells regulate the activity, survival, proliferation, migration and 
adhesion of local c-kit expressing cells as well as those in remote organs and tissues.   
1.4.2 SCF receptor c-kit 
The c-kit protein is a 145 KD glycoprotein encoded at the white spotting (W) 
locus on murine chromosome 5 187 and human chromosome 4q11-q12.188 It is mainly 
expressed on hematopoietic stem cells,173 prostate stem cells 189 and tumors.190 Recent 
studies also showed that it is a marker for various adult stem cells such as CSCs.122 In 
addition, mast cells, melanocytes in the skin, and interstitial cells of Cajal in the digestive 
tract, human aortic and umbilical vein endothelial cells also express c-kit.191-193 c-kit is a 
type III tyrosine kinase receptor characterized by an extracellular binding domain for 
SCF, a hydrophobic transmembrane region and an intracellular region with ATP binding, 
and phosphotransferase domain separated by a kinase insert.194 SCF forms a non-covalent 
homodimer that binds to 2 c-kit monomers and promotes c-kit dimerization, which results 
in autophosphorylation of c-kit cytoplasmic domain at tyrosine residues.195,196 The 
phosphotyrosine residues serve as docking sites for signal transduction molecules 
containing Src homology 2 (SH2) and other phosphotyrosine binding domains.194 There 
are multiple signaling pathways that can be activated by SCF/c-kit including MAP 
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kinase, PI3 kinase, phospholipase-γ (PLC-γ), Src and Janus kinase/signal transducers and 
activators of transcription (JAK/STAT) pathways, all of which contribute to the 
biological effects of SCF.197 SCF/c-kit signaling can be inhibited by blockage of SCF/c-
kit binding via neutralizing antibody, ACK2,198 or inhibition of c-kit receptor activation 
by AG 1296.199  
1.4.3 Potential Clinical Applications of SCF 
Recombinant human SCF is currently used to mobilize BMSCs for collection of 
HSCs for hematopoietic reconstitution200 and to prevent chemotherapy-induced anemia 
and thrombocytopenia.201  SCF has also been indicated as a drug target for cancer 
treatment.202,203 Analysis of serum SCF levels is recommended to aid the diagnosis of 
many diseases including pancreatic cancer,184 gastrointerstitial stromal tumor,204 primary 
uveal melanoma,205 acute renal allograft rejection,206 delayed and slow graft function207 
and Alzheimer’s disease.185  
The biological function of SCF in various diseases has also been widely 
investigated. SCF/c-kit signaling has been shown to have an anti-apoptotic role in acute 
kidney injury,208 diabetic neuropathy209 and steroid associated bone damage.210 
Furthermore, SCF can regulate endothelial cell and EPC function,211-214 leading to 
neovascularization in tissue repair. In synergy with granulocyte-colony stimulating factor 
(G-CSF), SCF is able to induce liver regeneration,215 reduce β-amyloid deposits in a 
mouse model of Alzheimer’s disease216 and enhance neuronal lineage commitment of 
neural stem cells.217 The role of SCF in IHD will be discussed in the following section. 
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1.4.4 SCF and IHD 
The role of granulocyte colony-stimulating factor (G-CSF) and S-SCF in MI was 
first studied by Orlic et al, showing enhanced BMSCs mobilization and recruitment to the 
infarcted heart and improved cardiac function in mice post-MI.68 Those beneficial effects 
resulted from decreased myocardial apoptosis,218 reduced arrhythmia,219 increased 
neovascularization 220 and impaired cardiac remodeling.221 However, Ohtsuka et al found 
SCF treatment alone failed to induce cardiac protective effects post-MI.220 Myocardial 
expression of SCF is decreased post-MI. Augmentation of SCF expression through 
transplanted MSCs has been shown to increase angiogenesis and cardiac function.222 
Moreover, cardiac transplantation of MSCs transfected with a full length mouse SCF 
cDNA plasmid, which express both S- and M-SCF, enhanced EPC recruitment and 
myocardial angiogenesis for about 2 weeks post-MI. However, there was no change in 
animal survival among all treatment groups.222 This is not surprising as more than 95% of 
the transplanted MSCs are cleared within 7 days following transplantation into the 
myocardium.223 Intra-myocardial administration of SCF sustainably mobilized 
exogenously administered Lin-c-kit+ bone marrow-derived cells from the circulation 
homing to the infarcted myocardium up to 72 hours post-MI, however, cardiac function 
was not investigated in this study.224 The molecular and cellular mechanisms by which 
SCF regulates cardiac function post-MI are not fully understood.  
1.5 OVERALL HYPOTHESIS AND AIMS 
IHD, a leading cause of death, is responsible for social and financial burden 
worldwide.1 Recently, treatment with S-SCF in combination with G-CSF was found to 
improve cardiac repair and survival after MI in mice.220 Furthermore, peri-infarct 
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injections of SCF increased recruitment of BMSCs to the infarcted heart.224 Although 
numerous animal studies using stem cell therapy showed significant protection post-MI, 
only minor improvements have been  observed in most clinical trials,113,114,225,226  while 
two recent trials showed no significant benefit at all.75,76,226 Thus, a better understanding 
of the pathophysiology of different types of stem cells in cardiac repair post-MI is 
needed.  
SCF is expressed as a glycosylated trans-membrane protein by many cells and 
tissues, including the myocardium.227 SCF binds to its receptor c-kit and plays a critical 
role in cell survival, proliferation, mobilization, and adhesion. c-kit positive adult stem 
cells including HSCs, EPCs and CSCs122,163,164 have been demonstrated to be potential 
candidates for cardiac repair post-MI, which implies a possible regulatory role of SCF in 
MI. M-SCF is more potent than S-SCF in supporting cell survival and proliferation.19 In 
adult mice lacking M-SCF, cardiac morphology and function at basal conditions were 
normal, but significantly higher mortality and worse cardiac function were observed post-
MI.228 To study the role of M-SCF in cardiac repair post-MI, we generated a novel mouse 
model of inducible cardiac specific over-expression of hSCF. The aim of this thesis was 
to study the effects of M-SCF on cardiac function post-MI and to investigate the 
underlying cellular mechanisms especially the role of M-SCF in regulation of c-kit+ 
stem/progenitor cell activity in the ischemic heart (Figure 1.4).  Our overall hypothesis 
was that cardiac-specific overexpression of hSCF protects the heart via inhibition of 
myocardial apoptosis and enhancement of neovascularization and stem cell activity 
post-MI.  
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Figure 1.4  Proposed cellular mechanisms by which membrane-associated SCF (M-
SCF) regulates cardiac function post-MI.  
Interaction of SCF with c-kit receptors improves cardiac repair post-MI by enhancing 
circulating stem cell and resident stem cell activities.  
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In order to induce cardiac-specific hSCF overexpression, a hSCF transgenic mouse was 
generated with the hSCF transgene expression under the control of a tetracycline-
responsive element containing the α-MHC promoter. The hSCF mice were then crossed 
with cardiac-specific tetracycline activator (tTA) mice to generate hSCF/tTA double 
transgenic mice. The hSCF/tTA transgenic mice specifically express the hSCF in the 
heart. These transgenic mice were healthy and fertile with no cardiac abnormalities.229 
Furthermore, myocardial expression of hSCF in hSCF/tTA mice can be abrogated by 
treatment with doxycycline (DOX). Thus, the specific effects of hSCF can be tested in 
the absence and presence of DOX to turn on and off hSCF expression in the heart.  
The first aim of this thesis was to determine the effects of hSCF on cardiac 
function and survival post-MI. Thus, in Chapter 2, I hypothesized that cardiomyocyte-
specific over-expression of hSCF improves myocardial function and survival post-MI. 
We found that the protective effects of hSCF post-MI were due to increased myocardial 
EPC population, decreased apoptosis and improved cardiac remodeling. The significant 
cardiac protection by hSCF at 5 and 30 days post-MI led to our query on the effects of 
hSCF in acute cardiac injury. Suggested by the observation that hSCF decreased 
myocardial apoptosis 5 days post-MI, the second aim was to determine the potential of 
hSCF to limit the infarct size after acute I/R.28,30 Moreover, Akt phosphorylation was 
increased in hSCF over-expressing myocardium 5 days post-MI. Thus, in Chapter 3 I 
hypothesized that cardiomyocyte-specific over-expression of hSCF decreases infarct size 
via Akt signaling after acute I/R. Interestingly, our results showed that decreased infarct 
size in hSCF over-expressing mice after acute I/R resulted from increased CD45+ckit+ 
cell retention and CD45-ckit+ CSCs activation in the myocardium. Besides EPCs and 
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CSCs, recent studies have shown that EPDCs are another potential resource of 
cardiovascular progenitors.230 Thus, the third aim of my thesis was to investigate the role 
of hSCF in EPDC activation, migration into the sub-epicardium and contribution to 
cardiac repair post-MI.161 So I hypothesized in Chapter 4 that cardiac specific over-
expression of hSCF promotes epicardial activation. We found that hSCF overexpression 
increased EPDC activation, proliferation and mobilization which contribute to 
myocardial neovascularization post-MI. 
In summary, the overriding aim of this thesis was to examine the cellular and 
molecular mechanisms that mediate the cardio-protective and beneficial effects of hSCF 
post-MI in mice. To accomplish this goal, experiments utilized both in vivo models of 
cardiac I/R and MI, and in vitro cultures of cardiomyocytes and EPDCs. The effects of 
hSCF on cardiac function and animal survival 30 days post-MI, changes in infarct size 
after acute I/R, and its impact on adult stem cell retention, activation, migration and 
differentiation were examined. 
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2 Chapter 2 
Cardiomyocyte Specific Overexpression of Human Stem Cell Factor Improves 
Cardiac Function and Survival post-Myocardial Infarction in Mice 
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69 
 
2.1 CHAPTER SUMMARY 
S-SCF has been shown to mobilize bone marrow stem cells and improve cardiac 
repair post-MI. However, the effect of M-SCF on cardiac remodeling post-MI is not 
known. This chapter investigated the effects of cardiomyocyte specific overexpression of 
membrane-associated hSCF on cardiac function post-MI. A novel mouse model with 
tetracycline-inducible and cardiac-specific overexpression of membrane-associated hSCF 
was generated. MI was induced by left main coronary artery ligation. This chapter 
illustrates that cardiac-specific overexpression of membrane-associated hSCF improved 
30-day mortality and cardiac function post-MI. Moreover, increased angiogenesis and 
decreased myocardial apoptosis and remodeling were observed.  Importantly, the EPC 
population was increased in hSCF overexpressing myocardium post-MI. Furthermore, 
hSCF overexpression promoted de novo angiogenesis as assessed by matrigel 
implantation into the LV myocardium. This data demonstrate that cardiomyocyte specific 
overexpression of hSCF improves myocardial function and survival post-MI. These 
beneficial effects of hSCF may result from increases in EPC retention, 
neovascularization, and decreases in myocardial apoptosis and cardiac remodeling. 
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2.2 INTRODUCTION 
MI is responsible for about one third of heart failure cases and causes 
approximately 2 million deaths per year worldwide.1 MI leads to scar formation and 
subsequent ventricular remodeling, which is characterized by infarct expansion, 
progressive fibrous replacement of myocardium, hypertrophic growth of the non-infarct 
myocardium and LV dilatation. Cardiac remodeling contributes to development of HF 
post-MI.2 Despite optimal pharmacological treatment, the prognosis of heart failure 
remains poor.3  
SCF, also known as Steel factor, mast cell growth factor, or c-kit ligand, binds to 
its receptor c-kit and promotes survival, proliferation, mobilization, and adhesion of all c-
kit expressing cells, which includes HSCs, EPCs,4,5 and CSCs.6 SCF is expressed as a 
glycosylated transmembrane protein by many cells and tissues including stromal cells, 
fibroblasts, endothelium, and myocardium.7,8 Alternative splicing leads to 2 isoforms of 
SCF, soluble (S-SCF) and membrane-associated (M-SCF) isoforms, which differ in the 
absence or presence of a proteolytic cleavage site encoded by exon 6. S-SCF and M-SCF 
have distinct but overlapping roles. M-SCF, the dominant isoform in vivo, induces a more 
persistent receptor activation and is more effective at promoting long-term support of 
target cell survival.9,10 Transgene expression of M-SCF in Steel-dickie (sld) mutant mice 
resulted in a significant relief from anemia and bone marrow hypoplasia.11 In contrast, 
overexpression of S-SCF transgene had no effect on red blood cell production but 
corrected the myeloid progenitor cell deficiency seen in these mutants.11 Recently, 
treatment with S-SCF in combination with G-CSF improved cardiac repair and survival 
post-MI while S-SCF treatment alone did not.12 Since M-SCF has a much different 
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biological profile compared to S-SCF, it is possible that cardiac specific overexpression 
of M-SCF may promote cardiac repair mechanisms post-MI.  
We hypothesized that inducible cardiomyocyte specific overexpression of human 
M-SCF (hSCF) could improve cardiac repair, myocardial function and survival post-MI. 
To test this hypothesis, we generated a novel transgenic mouse that overexpresses 
membrane-associated hSCF in cardiomyocytes under the control of a Tet-off system.13 
We demonstrated that cardiomyocyte-specific hSCF overexpression increased 
myocardial neovascularization, decreased ventricular remodelling, and increased survival 
post-MI. Our study suggests a novel therapeutic potential of hSCF in the treatment of 
heart failure post-MI. 
2.3 METHODS 
2.3.1 Generation of hSCF/tTA Double Transgenic Mice 
A new line of tetracycline-inducible cardiac-specific overexpressing membrane-
associated hSCF mice was generated as previously described.13 Briefly, membrane-
associated hSCF cDNA (accession #: NM_003994) was inserted into the inducible α-
myosin heavy chain (MHC) promoter expression vector 1 to permit DOX-regulated 
expression in combination with a cardiac-specific tTA-expressing transgene. The 
fragment containing tetracycline operon, α-MHC promoter and hSCF was injected into 
the fertilized oocytes, which were then transferred into the oviduct of a pseudo-pregnant 
female mouse. hSCF transgenic founders were verified by Southern blot analysis. 
Transgenic line 1 mice were used in the present study. The hSCF mice were crossed with 
mice created previously that carry tTA driven by α-MHC promoter 13 to produce wild 
type (WT), tTA, hSCF, and hSCF/tTA mice. Genotypes were identified by PCR using 
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genomic DNA from tail biopsies. The following primer pairs were used: tTA, forward, 
AGC GCA TTA GAG CTG CTT AAT GAG GTC, reverse, GTC GTA ATA ATG GCG 
GCA TAC TAT C; hSCF, forward, CAA CTG CAG GTC GAC CTG TTT GTG CTG 
GAT CGC AGC, reverse, CCC AAG CTT GAA GCA AAC ATG AAC TGT TACC. To 
turn off hSCF expression, the hSCF/tTA mice were treated with 0.2 mg/ml DOX in their 
drinking water for 2 weeks prior to and continued for 5 or 30 days after sham or MI 
surgery. 
2.3.2 Determination of mRNA Expression by Real-time RT-PCR 
Total RNA was extracted from heart tissue using Trizol and cDNA was 
synthesized using moloney murine leukemia virus (MMLV) reverse transcriptase as 
previously described.14 Real-time PCR was conducted using SYBR Green PCR Master 
Mix as per the manufacturer’s instructions (Eurogentec, CA). 28S rRNA was used as a 
loading control. The primer sequences were as follows: hSCF upstream 5’TCA TTC 
AAG AGC CCA GAA CC3’ and downstream 5’CAG ATG CCA CTA CAA AGT 
CC3’and 28S rRNA upstream 5' TTG AAA ATC CGG GGG AGA G 3' and downstream 
5' ACA TTG TTC CAA CAT GCC AG 3'. Samples were amplified for 35 cycles using 
MJ Research Opticon Real-time PCR machine. For quantification of the growth factors 
mRNA level in the heart, the following primer pairs were used: VEGF-A, forward, GAT 
TGA GAC CCT GGT GGA CAT C, reverse, TCT CCT ATG TGC TGG CTT TGG T; 
insulin growth factor (IGF-1), forward, CTG CTT GCT CAC CTT CAC CA, reverse, 
ATG CTG GAG CCA TAG CCT GT; bFGF, forward, CAA GGG AGT GTG TGC CAA 
CC, reverse, TGC CCA GTT CGT TTC AGT GC; mouse SCF, forward, CGG GAT 
GGA TGT TTT GCC TA, reverse, CTT CGG TGC GTT TTC TTC CA. The levels of 
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mRNA expression in relation to 28S were determined using a comparative threshold 
cycle (Ct) method as we previously described.14 
2.3.3 Animal Procedures 
Animals in this study were handled in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institute of Health (NIH 
publication No. 85-23, revised 1996) and approved by the Animal Use Subcommittee at 
the University of Western Ontario, Canada. After mice were anaesthetized with an IP 
injection of a mixture of ketamine (50 mg/kg) and xylazine (12.5 mg/kg), myocardial 
infarction was induced by surgical occlusion of the left main coronary artery through a 
left anterolateral approach as we previously described.15 Both male and female mice at 
the age between 2-6 months of age were randomly selected to undergo coronary artery 
ligation or sham surgery (same procedure without occlusion of the left main coronary 
artery). The investigator was blinded to the genotype of the mice during surgeries. 
Experiments were performed 5 or 30 days after surgery. Survival was monitored 
and the LV to body weight ratio was recorded. Infarct size was measured after animals 
were sacrificed and was expressed as a fraction of the total cross-sectional endocardial 
circumference of the LV as we described previously.15  
2.3.4 Hemodynamic Measurements 
Mice were anaesthetized as described in the previous section. A Millar pressure-
conductance catheter (Model SPR-839, Size 1.4F) was inserted into the right carotid 
artery and advanced into the LV. After stabilization for 10 minutes, the signal was 
recorded continuously and later analyzed with a cardiac pressure-volume analysis 
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program (PVAN 3.2; Millar Instruments, TX).15,16 Mice were then sacrificed and hearts 
were fixed in 4% paraformaldehyde or stored at -80°C for further analysis. 
2.3.5 Histology 
To measure myocyte cell size, cardiac tissue sections were stained with 
hematoxylin/eosin and photographed using a digital camera attached to a microscope 
(Observer D1, Zeiss) at a magnification of 400x. Myocyte shortest cross sectional 
diameters 17 at nuclei level were assessed by the AxioVision software. To study stem cell 
recruitment, tissue sections were stained with rabbit anti-mouse c-kit (1:200, Santa Cruz 
Biotechnology, CA) and rabbit anti-mouse VEGFR2 primary antibody (1:200, Abcam, 
MA) followed by goat anti-rabbit fluorescent secondary antibody. Nuclei were stained 
with Hoechst 33342. Ten to 15 fields of the peri-infarct area (200-300 µm adjacent to the 
infarct) were examined for each heart using a fluorescent microscope (Observer D1, 
Zeiss) at 630x magnification to quantify the c-kit positive and c-kit/VEGFR2 double 
positive cells. Images were taken using a laser confocal microscope (LSM 510 Meta, 
Zeiss). To analyze capillary density, tissue sections were stained with biotinylated lectin Ι 
(1:100, Vector Laboratory,CA) followed by Vectastain Elite ABC peroxidise kit with 
diaminobenzidine tetrahydrochloride (DAB) as a chromogen, and counterstained by 
hematoxylin. Ten to 14 images were taken in the peri-infarct area of each heart using a 
digital camera attached to a microscope (400x, Observer D1, Zeiss). To quantify the mast 
cells in the heart, cardiac tissue sections were stained with 0.02% toluidine blue in 0.25% 
acetic acid (pH 2.0-2.5).18,19 Two to 4 heart sections of each mouse were evaluated. 
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2.3.6  Caspase-3 Activity and Cytoplasmic Histone-Associated DNA Fragments 
Caspase-3 activity and cytoplasmic histone-associated DNA fragments were 
measured using caspase-3 cellular activity assay kit (BIOMOL, Plymouth Meeting, PA) 
and cell death detection enzyme-linked immunosorbent assay (ELISA) (Roche, 
Mississauga, ON), respectively as we previously described.20 
2.3.7 In vivo Matrigel Angiogenesis 
In vivo angiogenesis was assessed by myocardial matrigel implantation as 
described.21 Three days after matrigel implantation, heart tissues were collected and 
embedded in paraffin. Sections were cut and stained with hematoxylin and eosin. Results 
are expressed as the percentage of the vessel-like area to the total matrigel area. 
2.3.8 Statistical Analysis 
Data are expressed as the mean ± SEM. One- or two-way ANOVA followed by 
Bonferroni test was performed for multiple group comparisons. Unpaired Student’s t test 
was used to detect significance between two groups. Kaplan and Meier survival curves 
were analyzed by Log-rank (Mantel-Cox) test. Differences were considered significant at 
the level of P<0.05. 
2.4 RESULTS 
2.4.1 Generation and Characterization of the Conditional Cardiac-specific 
hSCF/tTA Double Transgenic Mice  
hSCF mice were generated with the hSCF transgene expression under the control 
of a tetracycline-responsive element containing the α-MHC promoter (Figure 2.1A). The 
hSCF transgenic mice were then crossed with cardiac-specific tTA mice to generate the  
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Figure 2.1 Generation and characterization of the inducible hSCF/tTA transgenic 
mouse.  
A, Illustration of the hSCF transgenic constructs used to create the hSCF transgenic mice. 
B, Expression of membrane-associated hSCF mRNA was detected in the heart, but not in 
other organs of hSCF/tTA mice in the absence of DOX.  C, Cardiac expression of 
membrane-associated hSCF mRNA in hSCF/tTA mice after treatment with DOX for 5, 
10 and 14 days. D, Protein expression of human SCF in heart tissue was measured by 
western blotting. Human SCF protein was exclusively expressed in hSCF/tTA-DOX 
mice. E, Endogenous mouse SCF mRNA expression determined by real-time PCR was 
not significantly different among WT, hSCF/tTA-DOX and hSCF/tTA+DOX mice. Data 
are mean ± SEM, n=5-7 per group. One-way ANOVA followed by Bonferroni test. 
77 
 
 
78 
 
inducible cardiac-specific hSCF/tTA double transgenic mice. The resulting offspring 
were genotyped by PCR using both tTA and hSCF primers. Cardiac specific expression 
of hSCF was verified by Real-time-PCR. Expression of hSCF was detected in the heart 
tissue but not in liver, kidney, skin, lung or skeletal muscle (Figure 2.1B).The inducible 
expression of hSCF in cardiomyocytes was verified using both RT-PCR and western blot 
techniques. Results showed a high level of hSCF mRNA and protein expression in the 
hearts of hSCF/tTA mice in the absence of DOX. After 10-14 days of continuous DOX 
administration, the expression of hSCF in hSCF/tTA mice was abrogated in both mRNA 
and protein levels (Figure 2.1C and D). Transgene expression did not affect endogenous 
mouse SCF expression as myocardial mouse SCF mRNA levels analyzed using real-time 
RT-PCR were similar among WT, hSCF/tTA-DOX and hSCF/tTA+DOX mice (Figure 
2.1E). Furthermore, there were no coat color changes in any of the hSCF/tTA mice. 
2.4.2 Post-MI Stem Cell Factor Expression 
A total of 87 hSCF/tTA mice and 105 littermates (tTA, hSCF and WT) were 
subjected to coronary artery ligation or sham operation. General characteristics of these 
animals are shown in Table 2.1. There were no statistical differences in age, sex or body 
weight between hSCF/tTA and littermates within sham or MI groups (P=n.s.). Protein 
expression of mouse SCF post-MI was studied by western blot analysis in WT mice. 
Myocardial mouse SCF protein levels were significantly lower at 5 days (P<0.05, Figure 
2.2A) but not at 30 days (P=n.s, Figure 2.2B) post-MI compared to sham group. The 
expression of hSCF mRNA as determined by real-time RT-PCR in hSCF/tTA mice was 
unchanged in the peri-infarct area at 5 days (Figure 2.2C) and 30 days (Figure 2.2D)  
79 
 
Table 2.1 General information of control and hSCF/tTA mice subjected to sham or 
MI surgeries 
Body Weight, g 27.8±0.9 26.0±0.8 26.6±0.6 26.5±0.6 
Infarct Size (% of LV) - - 38.6±0.8 38.5±0.7 
 
Data are mean ± SEM and analyzed by two-way ANOVA with Bonferroni test for age, 
sex and body weight. Infarct size was compared by Student’s t test. There was no 
statistical difference between control and hSCF/tTA mice in any of the parameters listed 
between the sham or MI group. Controls include WT, tTA and hSCF mice. Total number 
of animals includes all 5- and 30-day groups as well as DOX treatment groups.   
 
 
Sham 
                           MI  
Parameters Controls hSCF/tTA Controls  hSCF/tTA 
N 24 21 81 66 
Age at surgery, days 85±4 83±6 83±3 86±3 
Sex, M/F 24/0 21/0 13/68 10/56 
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Figure 2.2 Mouse SCF expression in the heart post-MI.  
Myocardial mouse SCF protein levels at 5 days (A) and 30 days (B) post-MI were 
measured by western blot analysis in WT mice. Compared to sham group, mouse SCF 
protein levels were significantly lower at 5 but not 30 days post-MI. Human SCF mRNA 
expression was detected in hSCF/tTA mice at 5 days (C) and 30 days (D) post-MI by 
real-time RT-PCR. There was no significant change in cardiac hSCF expression in 
hSCF/tTA mice post-MI. Data are mean ± SEM, n=4-5 per group. One-way ANOVA 
followed by Bonferroni test, *P<0.05 vs Sham. 
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post-MI compared to sham. 
2.4.3  Survival and Cardiac Function Post-MI 
Post-operation survival was monitored for 30 days in WT and hSCF/tTA sham 
groups, and in WT and hSCF/tTA MI groups (n=13, 11, 37 and 34, respectively). 
Survival of sham animals was 100%. MI resulted in significantly lower survival 
compared to sham groups (P<0.05). However, the 30-day survival of hSCF/tTA MI mice 
was significantly higher compared to WT mice (85% vs. 54%, P<0.05, Figure 2.3A).  
To evaluate the effect of cardiac-specific hSCF expression on cardiac function, 
LV hemodynamic parameters were analysed by a pressure-volume analysis system 5 and 
30 days post-MI. There was no significant difference in heart rate, mean arterial pressure, 
or cardiac output between hSCF/tTA and littermate controls (Table 2.2 and 2.3). Five 
days post-MI, cardiac function of WT MI mice as determined by LV +dP/dt, -dP/dt and 
preload adjusted maximum power (PAMP) was significantly lower as compared to sham 
groups (P<0.05, Figure 2.4). In the absence of DOX, which expresses hSCF, LV +dP/dt, 
-dP/dt and PAMP were preserved in hSCF/tTA MI mice (hSCF/tTA MI vs. WT MI, 
P<0.05, Figure 2.4). The preservation of cardiac function was completely blocked by 
DOX treatment, which turned off hSCF expression (hSCF/tTA+DOX MI vs. hSCF/tTA 
MI, P<0.05, Figure 2.4). Thirty days post-surgery, LV +dP/dt, -dP/dt and ejection 
fraction were significantly lower in WT, tTA and hSCF MI groups compared to WT 
sham (P<0.05, Figure 2.3B). Overexpression of hSCF preserved cardiac function 
(hSCF/tTA MI vs. WT, tTA and hSCF MI groups, P<0.05, Figure 2.3B). Furthermore, 
LV end diastolic volume was significantly higher in WT, tTA and hSCF MI groups 
compared to WT sham, but function was preserved in hSCF/tTA MI mice compared to  
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Figure 2.3 Survival and LV function 30 days post-MI.  
A, Mortality was significantly lower in the hSCF/tTA MI group compared with WT MI 
(Log-rank test). B, Changes in LV dP/dt (change of pressures over time), ejection fraction 
(LVEF) and LV end diastolic volume 30 days post-MI. Both systolic and diastolic 
functions were significantly improved in hSCF/tTA MI mice, which were abrogated by 
DOX treatment. Data are mean ± SEM, n=5-8 per group. Two-way ANOVA followed by 
Bonferroni test: *P<0.05 vs sham groups; † P<0.05 vs WT MI; ‡ P<0.05 vs hSCF/tTA 
MI. 
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Table 2.2 Hemodynamic parameters of WT and hSCF/tTA mice 5 days post-MI 
Parameters   WT hSCF/tTA P Value 
n 6 5  
Heart rate, beats/min 362±26 354±20 0.82 
MAP, mmHg 93±6 90±8 0.88 
LVEF, % 23±4 40±3 0.01  
SW, mW 171±35 441±111 0.07 
CO, µL/min 2087±293 3089±628 0.20 
PAMP, mW/mL2 31±9 75±10 0.008  
 
Data are mean ± SEM and analyzed by unpaired Student’s t test. MAP, mean arterial 
pressure; LVEF, left ventricle ejection fraction; SW, stroke work; CO, cardiac output; 
PAMP, preload adjusted maximum power. 
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Table 2.3 Hemodynamic parameters of control and hSCF/tTA mice 30 days post-MI 
Parameters  WT tTA hSCF hSCF/tTA P 
Value 
n  6 5 5 6  
Heart rate, beats/min 326±25 323±12 311±29 318±21 0.97 
MAP, mmHg 87±5 83±8 76±7 85±5 0.63 
LVEF, % 31±7 32±5 28±7 58±7 0.01  
SW, mW 438±219 509±150 409±114 700±298 0.77 
CO, µL/min 4052±1302 3895±744 3635±1134 4027±867 0.99 
PAMP, mW/mL2 24±4 38±15 46±25 212±45 0.0003  
 
Data are mean ± SEM and analyzed by one-way ANOVA followed by Bonferroni test. P 
values are comparisons between WT and hSCF/tTA mice. Abbreviations are the same as 
in Table 2.   
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Figure 2.4 Cardiac function 5 days post-MI.  
hSCF/tTA MI group had preserved LV function compared to WT MI. The improvement 
was abrogated in hSCF/tTA+DOX group. No difference in heart rate was found between 
groups. Data are mean ± SEM, n=5-6 per group. Two-way ANOVA followed by 
Bonferroni test: *P<0.05 vs sham groups; † P<0.05 vs WT MI; ‡ P<0.05 vs hSCF/tTA 
MI. 
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other MI groups (P<0.05, Figure 2.3B). However, the preserved cardiac function in 
hSCF/tTA mice 30 days post-MI was abrogated by DOX treatment (Figure 2.3B). 
2.4.4 Myocardial Apoptosis 5 days Post-MI 
To investigate mechanisms responsible for preserved cardiac function by cardiac-
specific hSCF overexpression, myocardial apoptosis in the peri-infarct area was studied 5 
days post-MI. Myocardial apoptosis was determined by both caspase-3 activity and cell 
death ELISA. Both caspase-3 activity and cytosolic DNA fragments were significantly 
higher in the WT MI group compared to the sham groups (P<0.05) while these indices 
were significantly lower in the hSCF/tTA MI mice compared with the WT MI group 
(P<0.05, Figure 2.5A and 2.5B). The lower in apoptosis was abrogated in the 
hSCF/tTA+DOX MI group in which the expression of hSCF was turned off (P<0.05, 
Figure 2.5A and 2.5B).  
2.4.5 Stem Cell Recruitment and Growth Factors Release Post-MI 
Stem cell recruitment to the peri-infarct area of the myocardium was evaluated by 
c-kit and c-kit/VEGFR2 double staining. Since VEGFR2 and c-kit are well-recognized 
markers for EPCs, cells positive for c-kit/VEGFR2 are likely EPCs. Representative 
fluorescent photomicrographs at 5 and 30 days post-MI are shown in Figure 2.6A and 
Figure 2.7A. Quantitative analysis showed that there were significantly more c-kit+ and 
c-kit+/VEGFR2+ cells retained in the peri-infarct area in hSCF/tTA compared to WT 
mice 5 days post-MI (P<0.05, Figure 2.6B).  Treatment with DOX which turns off hSCF 
expression abrogated the recruitment of c-kit+ and c-kit+/VEGFR2+ cells (P<0.05, Figure 
2.6B). Interestingly, 80% of the cells were c-kit+/VEGFR2+, indicating that majority of  
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Figure 2.5 Myocardial apoptosis in the peri-infarct area 5 days post-MI.  
Expression of hSCF in hSCF/tTA-DOX MI mice had significantly lower apoptosis as 
measured by caspase-3 activity (A) and cell death ELISA (B). These effects were 
abrogated by turning off the expression of hSCF in hSCF/tTA+DOX MI mice. Data are 
mean ± SEM, n=5-8. Two-way ANOVA followed by Bonferroni test: *P<0.05 vs Sham; 
† P<0.05 vs WT MI; ‡ P<0.05 vs hSCF/tTA MI. 
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Figure 2.6 c-kit+ and c-kit+/VEGFR2+ cells retained in the peri-infarct area 5 days 
post-MI.  
A, Representative confocal images of Hoechst (blue, nuclei), c-kit (red) and VEGFR2 
(green) staining. Panel 3 in A shows a capillary positive for c-kit (*) and a capillary 
positive for both c-kit and VEGFR2 (**) in hSCF/tTA mice. Arrows, positive signals; 
arrowheads, red blood cells. B, Quantitative analysis of c-kit+ and c-kit+/VEGFR2+ cells 
in the peri-infarct area. Data are mean ± SEM, n=5-8. One-way ANOVA followed by 
Bonferroni test: *P<0.05 vs WT MI, † P<0.05 vs hSCF/tTA-DOX MI.  
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Figure 2.7 c-kit+ and c-kit+/VEGFR2+ cells retained in the peri-infarct area 30 days 
post-MI.  
A, Representative confocal images of Hoechst (blue, nuclei), c-kit (red) and VEGFR2 
(green) staining; B, Quantitative analysis of c-kit+ and c-kit+/VEGFR2+ cells in the peri-
infarct area, Data are mean ± SEM, n=5. Unpaired Student’s t test: * P<0.05 vs WT.   
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the stem cells were EPCs. Furthermore, capillaries in the peri-infarct area were positive 
for c-kit and VEGFR2 in the hSCF/tTA mice (Figure 2.6A, panel 3), suggesting 
incorporation of EPCs into the newly formed vessels. At 30 days post-MI, myocardial 
stem cell density in the peri-infarct area was at similar low levels in both WT and 
hSCF/tTA mice (Figure 2.7B).  
Mast cells also express c-kit. To analyze myocardial mast cell density, heart 
sections were stained using toluidine blue. Consistent with previous studies, there were 
very few mast cells in sham or infarct myocardium in WT mice 19 and no significant 
difference in mast cells  was observed in hSCF/tTA mice in either 5 or 30 days post-MI 
(Table 2.4 and Figure 2.8). Thus, the influence of mast cells on c-kit+ stem cell analysis 
in the infarct myocardium is negligible in the present study. Previous studies have 
implicated growth factors including VEGF-A, IGF-1 and bFGF in cardiac repair post-
MI.22 To determine expression of these growth factors, real-time RT-PCR was employed. 
The mRNA levels of VEGF-A, IGF-1 and bFGF in the peri-infarct area 5 days post-MI 
were significantly higher in hSCF/tTA compared to WT mice (P<0.05, Figure 2.9). 
2.4.6 LV Hypertrophy 30 days Post-MI 
The LV weight to body weight ratio, a measure of LV hypertrophy, was similar 
between sham groups, but was significantly higher in WT MI mice compared to WT 
sham (P<0.05, Figure 2.10A). However, the ratio in hSCF/tTA MI mice was 
significantly lower when compared with WT MI mice (P<0.05, Figure 2.10A). MI-
induced LV hypertrophy was further studied at the cellular level by histological analysis. 
Representative photomicrographs of hematoxylin and eosin stained sections are shown in 
Figure 2.10B. Myocyte transverse diameters were assessed using the minimum cross- 
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Table 2.4 Number of mast cells in the left ventricular myocardium 5 and 30 days 
after sham or MI surgeries. 
Groups Mouse 
genotype 
Sub-
epicardium 
Non-infarct Peri-infarct  
5-day sham  WT 1.7±0.8 3.1±1.0 -  
 
hSCF/tTA 2±1.1 2.6±1.2 -  
5-day MI WT 2.3±1.0  0.4±0.2 1.4±0.3  
 hSCF/tTA 0.7±0.4  0.2±0.2 0.9±0.4  
30-day sham WT 1.4±0.4  1.9±0.8 -  
 hSCF/tTA 0.9±0.9  1.0±0.7 -  
30-day MI WT 2.3±0.9  1.1±0.8 0.6±0.2  
 hSCF/tTA 2.3±0.1  0.0±0.0 0.7±0.5  
 
Data are mean ± SEM of mast cells per heart section from 4 animals per group. Two-way 
ANOVA followed by Bonferroni test. There was no statistical difference between any 
groups.  
  
 
98 
 
Figure 2.8 Mast cell staining using toluidine blue in heart tissue sections from WT and 
hSCF/tTA mice.  
Mice were subjected to sham or myocardial infarction (MI) for 5 or 30 days. Arrows 
indicate mast cells. Infarct area is labeled. 
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Figure 2.9 Growth factor expression in the peri-infarct area 5 days post-MI. 
 Myocardial VEGF-A, IGF-1 and bFGF mRNA were determined by real-time RT-PCR 5 
days post-MI. Data are mean ± SEM, n=6. Unpaired Student’s t test: * P<0.05 vs WT.   
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Figure 2.10 LV hypertrophy 30 days post-MI or sham operations.  
A, LV to body weight ratios. B, Representative photomicrographs of hematoxylin and 
eosin stained sections showing the cross-sections of cardiomyocytes. C, Quantitative 
analysis of myocyte diameters in WT and hSCF/tTA mice in the presence or absence of 
DOX. Data are mean ± SEM, n=5-11; Two-way ANOVA followed by Bonferroni test: 
*P<0.05 vs sham groups; † P<0.05 vs WT MI. 
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sectional diameter at the nuclear level to reduce the effects of myocyte orientation on cell 
size measurements.17 The minimum cross-sectional diameter was similar between sham 
groups but was significantly higher in the WT MI compared to WT sham (P<0.05, 
Figure 2.10C). However, the hSCF/tTA MI mice showed significantly smaller myocyte 
cross-sectional diameters compared to those of WT MI mice (P<0.05, Figure 2.10C). 
Furthermore, these effects were abrogated when hSCF expression was turned off by 
DOX treatment (Figure 2.10A and 2.10C). 
2.4.7 Capillary Density post-MI 
To quantify myocardial capillary density, lectin-Ι was employed to specifically 
stain endothelial cells. Representative photomicrographs of lectin-Ι staining are presented 
in Figure 2.11A (5 days post-MI) and Figure 2.12A (30 days post-MI). In mice 5 days 
post-surgery, myocardial capillary density was similar between WT and hSCF/tTA sham 
mice (Figure 2.11B). The capillary density in the peri-infarct area of the MI group was 
significantly lower compared to the sham groups (P<0.05, Figure 2.11B). When hSCF 
expression was activated in the hSCF/tTA mice in absence of DOX, capillary density was 
significantly higher (hSCF/tTA MI vs. WT MI, P<0.05, Figure 2.11B). However, this 
was abrogated by DOX treatment in hSCF/tTA mice (hSCF/tTA+DOX MI vs. hSCF/tTA 
MI, P<0.05, Figure 2.11B). Capillary density was also assessed 30 days post-surgery. 
Myocardial capillary density was similar between WT and hSCF/tTA sham mice (Figure 
2.12B). Capillary density in the peri-infarct area of the MI groups was significantly lower 
compared to the respective sham groups (P<0.05, Figure 2.12B). Overexpression of 
hSCF had significantly higher capillary density (hSCF/tTA MI vs. WT MI, P<0.05,  
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Figure 2.11 Myocardial capillary density 5 days post-MI.  
Capillaries were identified by endothelial specific lectin-I staining in WT, hSCF/tTA and 
hSCF/tTA+DOX mice. A, Representative photomicrographs of lectin-I stained sections 
from each experiment group, showing individual capillaries (brown staining). Nuclei 
were stained by hematoxylin. B, Quantitative analysis of capillary density. Data are mean 
± SEM, n=5-6 per group. Two-way ANOVA followed by Bonferroni test: *P<0.05 vs 
sham; † P<0.05 vs WT MI; ‡ P<0.05 vs hSCF/tTA MI.  
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Figure 2.12 Myocardial capillary density 30 days post-MI.  
Capillaries were identified by endothelial specific lectin-I staining in WT, hSCF/tTA and 
hSCF/tTA+DOX mice. A, Representative photomicrographs of lectin-I stained sections 
from each experiment group, showing individual capillaries (brown staining). Nuclei 
were stained by hematoxylin. B, Quantitative analysis of capillary density. Data are mean 
± SEM, n=5-6 per group. Two-way ANOVA followed by Bonferroni test: *P<0.05 vs 
sham; † P<0.05 vs WT MI; ‡ P<0.05 vs hSCF/tTA MI. 
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Figure 2.12B). DOX treatment abrogated the higher capillary density in hSCF/tTA mice 
(Figure 2.12B). 
2.4.8 In Vivo Myocardial Angiogenesis 
The ability of the hSCF expressed in the cardiomyocytes to promote angiogenesis 
was investigated in vivo by implanting matrigel into the LV myocardium for 3 days. As 
shown in Figure 2.13A, the matrigel was surrounded by inflammatory cells and could be 
easily identified in the myocardium. The newly formed vessels that penetrated into the 
gel plug showed aneurysm-like structures inside the gel. The area of capillaries and 
aneurysm-like structures penetrating the matrigel plug was quantified in relation to the 
total matrigel area. The percentage of vessel-like areas was significantly higher in 
hSCF/tTA compared to those of WT mice (P<0.05, Figure 2.13B). 
2.5 DISCUSSION 
The present study demonstrates for the first time that cardiomyocyte-specific 
expression of membrane-associated hSCF preserves survival and cardiac function post-
MI. The beneficial effects of transgene expression are associated with lower myocardial 
apoptosis, higher recruitment of stem cells to the infarcted myocardium, enhanced 
myocardial neovascularization and lower ventricular remodeling. The preserved cardiac 
function and myocardial angiogenesis are a result of hSCF overexpression since 
treatment with DOX, which turns off hSCF expression, abrogates these effects post-MI. 
Our study suggests that hSCF may have therapeutic potential in the treatment of heart 
failure post-MI. 
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Figure 2.13 Myocardial angiogenesis WT and hSCF/tTA mice.  
Matrigel (M) was implanted into the LV myocardium for 3 days. A. Representative 
images of H/E stained heart sections. The lumens and the aneurysm-like structures are the 
newly formed vessels, which have grown into the matrigel. Arrows indicate epicardium. 
B. Quantitative analysis of angiogenesis. The area of capillary-like structures in relation 
to the total matrigel area was quantified and expressed as percent of vessel-like area. Data 
are mean ± SEM from 6 mice per group. Unpaired Student’s t test: *P<0.05 vs WT 
group.  
111 
 
 
 
112 
 
c-kit signaling can promote cardiac repair post-MI.  Administration of c-kit+ stem 
cells, whether using intravenous injection or local delivery into the infarcted myocardium 
post-MI, improves cardiac function, enhances angiogenesis and impairs cardiac 
remodeling.23,24 On the other hand, c-kit deficient (W/Wv) mice exhibit dilated 
cardiomyopathy post-MI. After replacement with normal WT bone marrow, the 
cardiomyopathic phenotype of W/Wv mice is rescued.25,26 However, the W/Wv mice have 
defects in hematopoietic stem cell function, abnormal islet beta-cell development and 
impaired glucose tolerance.27,28 These abnormalities also likely contribute to the impaired 
cardiac repair post-MI.  As the ligand of c-kit, soluble SCF is increased in the bone 
marrow after myocardial ischemia-reperfusion injury, leading to EPC mobilization and 
improvement in myocardial neovascularization and cardiac function.29 Furthermore, peri-
infarct injections of soluble SCF increased c-kit+ stem cell recruitment to the infarcted 
heart following intravenous administration of bone marrow derived stem cells.30 
Although this effect lasted for 72 hours, there was no functional benefit observed. 
Following MI, circulating c-kit+ bone marrow stem cells and EPCs are 
increased.31-33 However, stem cell attractants SDF-1 and SCF as well as pro-angiogenic 
genes such as VEGF-A and VEGFR2 are decreased in the infarct region post-MI.8 The 
stem/progenitor cells mobilized into the peripheral blood may not be recruited in 
sufficient numbers or retained in the infarcted myocardium to participate in cardiac repair 
because of decreased myocardial expression of stem cell attractants such as SCF.8 
In order to increase the recruitment and retention of stem/progenitor cells in the 
infarcted myocardium and to improve cardiac repair post-MI, a cardiomyocyte-specific 
membrane associated hSCF overexpressing mouse was generated in the present study. 
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Our model differs from the model reported by Kapur et al. in which overexpression of 
hSCF under the control of human phosphoglycerate kinase (hPGK) promoter inhibited 
normal SCF function in mice.34 These mice displayed forehead blaze with white spots 
over the cervical region and the belly as a result of melanocyte deficiency, and their 
endogenous SCF expression was diminished.35 The major difference between this mouse 
model and our transgenic mice is that their hPGK promoter directed hSCF expression in 
many organs including the skin, thymus, spleen, brain, bone marrow, and testes during 
embryonic development 34 while our mouse model is cardiac specific and hSCF was 
expressed only in the heart postnatally. Furthermore, our mice did not display any coat 
color deficiencies, and importantly, endogenous mouse SCF expression was not altered. 
Thus, we did not see any functional antagonism of hSCF in our model.  
Our data suggest that cardiac specific overexpression of hSCF may promote 
retention of c-kit+ cells including EPCs in the infarcted myocardium, which remains to be 
verified in future studies. Importantly, these cells participate in the angiogenic process as 
they were incorporated into the newly formed vessels in the infarcted myocardium. In 
addition, c-kit signaling can increase cell survival and stem cell function.36,37 Consistent 
with this hypothesis, myocardial capillary density was higher in the hSCF overexpressing 
mice post-MI. However, the relative contribution of enhanced cell survival versus 
angiogenesis to the effect of hSCF overexpression leading to higher capillary density is 
not clear.  Furthermore, although the absolute number of stem cells retained in the 
infarcted myocardium is only doubled with hSCF overexpression, it is possible that the 
preserved survival and functional capacity associated with these stem cells could result in 
the increased release of soluble factors, causing beneficial paracrine actions on the 
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myocardium.22 In support of this paracrine hypothesis, expression of several candidate 
mediators such as VEGF-A, bFGF, and IGF-1 was higher in the myocardium 
overexpressing membrane associated hSCF post-MI. Indeed, hSCF overexpression 
resulted in lower myocardial apoptosis and cardiac hypertrophy, leading to preserved 
cardiac function and survival post-MI. 
The effects of SCF on cardiac function have also been studied using cardiac 
transplantation of MSC transfected with a full length mouse SCF cDNA plasmid 
expressing both S- and M-SCF.38 Transplantation of MSCs containing SCF plasmids 
enhanced EPC recruitment and myocardial angiogenesis post-MI for about 2 weeks. 
However, there was no change in animal survival among all treatment groups. 
Furthermore, cardiac function determined at 4 weeks post-MI was not significantly 
improved by SCF transfection compared to the MSC group.38 This is not surprising as 
more than 95% of the transplanted MSCs are cleared within 7 days following 
transplantation into the myocardium.39 In the present study, in order to study the long-
term effects of SCF on the infarcted myocardium, we chose to express the membrane-
associated isoform of hSCF specifically in the heart. Thus hSCF expression was stable 
and sustained over the entire study period. hSCF expressed on the membrane of 
cardiomyocytes serves as a chemoattractant for circulating stem cells to migrate to, and 
stay in the myocardium. Furthermore, Tet-off system was employed, allowing for 
reversible cardiac expression of hSCF. Treatment with doxycycline turned off hSCF 
expression and reversed the beneficial effects of hSCF in mice with MI. Our data showed 
that cardiomyocyte specific hSCF overexpression resulted in angiogenesis, higher 
capillary density, less myocardial apoptosis, and less LV hypertrophy post-MI. These 
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beneficial effects led to significantly preserved in cardiac function and survival in 
hSCF/tTA mice post-MI, and are likely due to the enhanced recruitment and retention of 
EPCs to the infarct myocardium and thus improved cardiac repair. Cardiac regeneration 
via transdifferentiation from bone marrow stem cells in vivo post-MI is still debatable.23 
Whether hSCF overexpression promotes myocardial regeneration from resident cardiac 
stem cells requires further investigation. 
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3 CHAPTER 3 
Cardiomyocyte-Specific Overexpression of Human Stem Cell Factor Protects 
against Myocardial Ischemia and Reperfusion Injury 
 
 
 
 
 
 
 
 
 
 
A version of this chapter was accepted by International Journal of Cardiology, 2013: 
Xiang F, Lu X, Liu Y, Feng Q  
“Cardiomyocyte-Specific Overexpression of Human Stem Cell Factor Protects against 
Myocardial Ischemia and Reperfusion Injury.”  
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3.1 CHAPTER SUMMARY 
In Chapter 2, I demonstrated that cardiomyocyte-specific overexpression of 
hSCF preserves cardiac function and animal survival post-MI via enhanced retention and 
differentiation of EPCs. However, whether hSCF overexpression protects the heart from 
acute cardiac injury is not known. In this chapter, I investigated the effects of 
cardiomyocyte-specific overexpression of hSCF on acute myocardial I/R (45 min/3 h) 
injury and related signaling mechanisms. I found that infarct size and myocardial 
apoptosis after I/R were diminished by hSCF overexpression. These cardioprotective 
effects were related to increased PI3K/Akt/eNOS signaling pathways associated with 
increased myocardial insulin-like growth factor 1 (IGF-1) and hepatocyte growth factor 
(HGF) expression. Furthermore, enhanced retention of circulating c-kit+ cells and 
activation of resident cardiac stem cells (CSCs) contribute to the beneficial effects 
observed in hSCF overexpressing mice. Thus, cardiomyocyte-specific overexpression of 
hSCF protects the heart from acute I/R injury. The cardioprotective effects of hSCF 
overexpression are mediated by increased c-kit+ progenitors, enhanced growth factor 
expression and activation of the PI3K/Akt signaling pathway.  
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3.2 INTRODUCTION 
IHD is the leading cause of death worldwide.1 Following acute MI, re-
establishing coronary blood flow by thrombolysis or angioplasty is used to rescue the 
ischemic myocardium. However, reperfusion can also induce myocyte death by 
activation of deleterious signalling cascades.2 Therapeutic strategies for cardiac 
protection from I/R injury are needed. Studies on pre- and post-conditioning have shown 
that I/R injury initiates several pro-survival kinase cascades including the PI3K/Akt 
signaling pathway.3 A constitutively active Akt mutant (myr-Akt) has been shown to 
decrease myocardial apoptosis, infarct size and preserve cardiac function in rats after 
I/R.4 Akt activation leads to phosphorylation of multiple protein targets, including 
eNOS,5 which promote cell survival.6 Moreover, the beneficial effects of growth factors, 
including VEGF, IGF-1 and HGF,7 and pharmacological treatments such as statins and 
EPO, 5,8  on ischemic injury mainly result from Akt activation.  
SCF is a glycosylated trans-membrane protein widely expressed by many cells 
and tissues including stromal cells, fibroblasts, endothelium, and myocardium.9,10 It plays 
a critical role in the survival, proliferation, mobilization, and adhesion of all c-kit 
expressing cells including hematopoietic stem cells, EPCs, and CSCs.11-13 Alternative 
splicing of SCF leads to 2 isoforms: soluble (S-SCF) and membrane-associated (M-SCF) 
isoforms. M-SCF, the dominant isoform in vivo, is able to induce more persistent receptor 
activation and is more effective at promoting long-term support of target cell survival.14,15  
Binding of c-kit with SCF through autocrine or paracrine actions leads to oligomerization 
and auto-phosphorylation of the receptor which activates multiple downstream signalling 
pathways including PI3K/Akt. The PI3K/Akt pathway activated by SCF is responsible 
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for c-kit+ cell proliferation, differentiation, adhesion, secretion, survival, and actin 
cytoskeletal reorganization.11,16,17  
The previous chapter has demonstrated that cardiomyocyte-specific 
overexpression of hSCF improves cardiac function and animal survival post-MI in mice. 
The beneficial effects are due to increased c-kit+ cell recruitment, enhanced growth factor 
expression, decreased myocardial apoptosis, increased angiogenesis and reduced cardiac 
remodeling.  However, whether hSCF overexpression protects the heart from acute I/R 
injury remains to be determined. This is an important question as limiting myocardial 
ischemic injury is critical to preserve functional myocardium and prevent subsequent 
progression to heart failure. In this chapter, we hypothesized that inducible 
cardiomyocyte-specific overexpression of hSCF protects the heart from I/R injury. To 
test this hypothesis, a transgenic mouse that overexpresses hSCF in cardiomyocytes 
under the control of a Tet-off system was employed.18 We demonstrated that 
cardiomyocyte-specific hSCF overexpression protects the heart from I/R injury via 
increased c-kit+ cell activation, enhanced growth factor expression and Akt activation.  
3.3 METHODS 
3.3.1 Animals 
Animals in this study were handled in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institute of Health (NIH 
publication No. 85-23, revised 1996) and animal handling was approved by the Animal 
Use Subcommittee at the University of Western Ontario, Canada. The conditional 
cardiac-specific hSCF overexpressing hSCF/tTA transgenic mice were generated using 
an α-MHC promoter as described in Chapter 2. The first generation of hSCF/tTA mice 
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was from a C57BL6/CBA background and backcrossed to C57BL/6 for 16 generations 
prior to the present study. In total, 87 adult male hSCF/tTA and 95 WT mice (3-4 months 
old) were used.  
3.3.2 Myocardial I/R 
Induction of myocardial I/R was performed as previously described.19 Mice were 
anesthetized with an intraperitoneal (IP) injection of a mixture of ketamine (50 mg/kg) 
and xylazine (12.5 mg/kg) and then intubated and artificially ventilated with a respirator 
(SAR-830, CWE, Ardmore, PA., USA). The heart was exposed by a left intercostal 
thoracotomy. The pericardium was opened, and the left main coronary artery was 
occluded for 45 minutes by positioning a suture (8-0) around it secured with PE-10 
tubing. The tubing was then removed and the suture was loosened to allow reperfusion 
for 3 hours. The lungs were hyperinflated using positive end-expiratory pressures (3 cm 
H2O), and the thorax was closed. To inhibit Akt signaling, animals were treated with a 
PI3 kinase inhibitor LY294002 (Sigma, 7.5 mg/kg body weight, IP) 20,21 15 minutes 
before reperfusion. To inhibit c-kit signalling, mice were treated with a neutralizing 
antibody ACK2 (100 µg, IP, eBioscience, San Diego, CA, USA) 15 minutes before 
ischemia.22 To inhibit HGF receptor (c-Met) signaling, mice were treated with a c-Met 
inhibitor Crizotinib (15 mg/kg body weight, IP, Selleckchem, Houston, TX, USA) 15 
minutes before ischemia.23 To turn off hSCF overexpression, the hSCF/tTA mice were 
treated daily with DOX (0.2 mg/ml in drinking water) starting 2 weeks before surgeries.  
3.3.3 Measurement of Infarct Size 
Infarct size was calculated by infarct area to ischemic area ratio normalized by 
tissue weight.19 Briefly, the coronary artery was re-ligated after 3 hour reperfusion. Evans 
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blue dye solution (1% in PBS) was perfused through the coronary arteries via the 
cannulated aorta to distinguish ischemic and non-ischemic areas of the heart. Hearts were 
cut into four transverse slices from the apex to the base and incubated with 1.5% 
triphenyltetrazolium chloride (TTC, Sigma, St. Louis, MO, USA) in PBS for 30 min at 
room temperature. Sections were weighed and photographed. The non-ischemic area, 
area at risk, and infarct area were measured using SigmaScan Pro. 
3.3.4 Determination of Myocardial Apoptosis 
Caspase-3 activity and cytoplasmic histone-associated DNA fragments were 
measured using a caspase-3 cellular activity assay kit (BIOMOL, Plymouth Meeting, PA) 
and cell death detection ELISA (Roche, Mississauga, ON), respectively. Briefly, heart 
tissues from the ischemic area was removed and homogenized. After a 5-minute 
centrifugation at 12,000 x g at 4oC, supernatants were collected and protein 
concentrations were measured. To assess caspase-3 activity, supernatants from each heart 
containing 200 µg of protein were loaded into a 96-well plate and incubated at 37oC for 
16 hours in the presence of the caspase-3 substrate, Ac-DEVD-AMC (20 µM), or Ac-
DEVD-AMC, plus the inhibitor, Ac-DEVD-CHO (4 µM). Fluorescence intensity 
(excitation at 360 nm and emission at 460 nm) was measured using a Spectra-Max M5 
micro-plate reader (Molecular Devices, Sunnyvale, CA, USA). Data were expressed as 
amount of AMC substrate cleaved per 100 µg of protein. To assess cytoplasmic histone-
associated DNA fragments, supernatants containing 20 µg of protein were incubated in 
an anti-histone antibody coated 96-well plates for 90 minutes. The sample solutions were 
removed and horseradish peroxidise-conjugated anti-DNA antibody was added and 
incubated for 90 minutes. The color was developed by adding peroxidase substrate 
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(ABTS) and detected using a Spectra-Max micro-plate reader (Molecular Devices, 
Sunnyvale, CA, USA) at a wavelength of 405 nm.  
3.3.5 Western Blot Analysis 
Myocardial HGF and IGF-1 expression, and phosphorylated/total Akt and eNOS 
in peri-infarct area of the myocardium were measured by western blot analysis. Briefly, 
40-60 µg of protein were separated by 10-15% SDS-PAGE gel and transferred to 
nitrocellulose membranes, and blots were probed with antibodies against Akt (1:1000, 
ABM, Vancouver, BC, Canada), phosphorylated Akt (Ser473, 1:1000, ABM, Vancouver, 
BC, Canada), eNOS (1:500, Cell Signaling, Danvers, MA, USA), phosphorylated eNOS 
(1:500, Cell Signaling, Danvers, MA, USA), α-actinin (1:2500, Sigma, Oakville, ON, 
Canada), HGF (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), IGF-1 (1:500, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or GAPDH (1:3000, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Blots were then washed and probed with 
horseradish peroxidase conjugated secondary antibodies (1:3000, Bio-Rad, Hercules, CA, 
USA), and detected by using an ECL detection method. 
3.3.6 Growth Factor mRNA Expression 
Total mRNA was isolated from LV heart tissue with TRIzol reagent (Invitrogen, 
Grand Island, NY, USA). cDNA was synthesized using MMLV reverse transcriptase and 
random primers. Real-time PCR was conducted using SYBR Green PCR Master Mix 
(Eurogentec, San Diego, CA, USA). 28S rRNA was used as a loading control. The 
oligonucleotide primer sequences were as follows:  IGF-1, forward, CTG CTT GCT 
CAC CTT CAC CA, reverse, ATG CTG GAG CCA TAG CCT GT. HGF, forward, GTC 
AGC ACC ATC AAG GCA AG, reverse, TCC ACGACC AGG AAC AAT GA. 
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Samples were amplified for 35 cycles using an Eppendorf Mastercycler Real-Time PCR 
machine (Eppendorf, Hamburg, Germany).  The mRNA Levels were determined by the 
relative expression compared with that of 28S rRNA.  
3.3.7 Immunofluorescent Staining for Stem Cells 
Three hours after I/R, the heart was perfused with 10% potassium chloride to 
induce diastolic cardiac arrest followed by saline and 4% paraformaldehyde perfusion for 
15 minutes. After a 1 hour incubation in 30% sucrose, hearts were embedded in OCT and 
cut into 5 µm sagittal sections. The sections were stained with primary antibodies (c-kit, 
1:200, eBioscience, San Diego, CA, USA; Ki67, 1:200, NeoMarkers, Fremont, CA, 
USA) at 4oC for overnight followed by fluorescent secondary antibody at room 
temperature for 1 hour. CD45 was stained by FITC-conjugated anti-CD45 (1:100, 
eBioscience, San Diego, CA, USA) at 4oC for overnight. Nuclei were stained with 
Hoechst 33342. The number of c-kit+, Ki67+, CD45+/c-kit+ and CD45-/c-kit+ cells per 
sagittal heart section was quantified in a blind manner using a fluorescent microscope 
(Observer D1, Carl Zeiss Canada, Toronto, Canada). Images were taken using a laser 
confocal microscope (LSM 510 Meta, Carl Zeiss Canada, Toronto, Canada).  
3.3.8 Isolation and Culture of c-kit+ CSCs 
c-kit+ CSCs were isolated using a previous protocol 24,25 with modifications. 
Briefly, hearts from WT mice were isolated and perfused with cold PBS. LV was minced 
into small pieces and mild digested with 0.05% Trypsin-EDTA at 37oC for 15 minutes. 
LV pieces were then transferred to fibronectin coated dish and incubated in complete 
explant medium (IMDM, 15% fetal bovine serum, 1% penicillin–streptomycin, 1% L-
glutamine, 0.1 mM 2-mercaptoethanol) for 2-3 weeks. C-kit+ CSCs were isolated by c-kit 
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antibody (Santa Cruz, CA, USA) conjugated magnetic beads (Invitrogen, CA, USA) from 
cells mild digested (0.05% Trypsin-EDTA, room temperature, <3 minutes) from the 
incubated LV tissues and then incubated in CSC culture medium (DMEM/F-12, 3.5% 
FBS, 1% penicillin–streptomycin, 1% L-glutamine, 0.1 mM 2-mercaptoethanol, 80 
ng/mL bFGF and 25 ng/mL EGF) for further experiments. To investigate the effects of 
hSCF overexpression on growth factor expression, c-kit+ CSCs were seeded at density of 
2x104/well of 24-well plates and treated with adenoviral membrane-associate hSCF or 
LacZ constructs for 24 hours. ACK2 (20 µg/mL) was used to block c-kit signaling.   
3.3.9 Flow Cytometry 
The expression of CD45 in isolated CSCs was analyzed using a FACSCalibur 
(BD Biosciences, Mississauga, ON, Canada). After c-kit+ CSCs were pulled-down by c-
kit antibody (Santa Cruz, CA, USA) conjugated magnetic beads, the c-kit+ and c-kit- cells 
were stained with fluorescein isothiocyanate-conjugated monoclonal antibody against 
mouse CD45 (eBIOSCIENCE, San Diego, CA, USA). The percentage of CD45+ cells in 
c-kit+ and c-kit- cells was determined.  
3.3.10 Toluidine Blue Staining for Mast Cells 
To quantify mast cells in the heart, cardiac tissue sections were stained with 
0.05% toluidine blue (Sigma, St. Louis, MO, USA) in 1% sodium chloride for 2 minutes. 
The granules of mast cells show violet as we described in previous chapter.  
3.3.11   Statistical Analysis 
Data are expressed as the mean ± SEM. Two-way ANOVA followed by 
Bonferroni test was used for multiple group comparisons. Unpaired Student t-test was 
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used for two group comparisons. Differences were considered statistically significant at 
the level of P<0.05.  
3.4 Results 
3.4.1 Overexpression of hSCF Reduces Infarct Size and Myocardial Apoptosis 
after I/R 
Infarct sizes were measured in WT and hSCF/tTA mice. Representative images of 
heart sections following Evans blue and TTC staining are shown in Figure 3.1A. Forty-
five minutes of ischemia followed by 3 hours of reperfusion resulted in an infarct size of 
54% in WT mice. However, the infarct size of hSCF/tTA mice was significantly smaller 
(39%) compared to WT (P<0.05, Figure 3.1B). Accordingly, myocardial apoptosis 
measured by caspase-3 activity and cell death ELISA in the infarct border zone was 
significantly lower in hSCF/tTA mice compared to WT (P<0.05, Figure 3.2). To further 
verify that the protective effects were due to hSCF overexpression, hSCF/tTA mice were 
treated with DOX for 2 weeks to turn off the cardiac hSCF expression and then subjected 
to I/R. DOX treatment led to an infarct size of 52% in hSCF/tTA mice (Figure 3.1B). 
Myocardial apoptosis in DOX-treated hSCF/tTA mice was also increased to similar 
levels as the WT groups (Figure 3.2).  
3.4.2 Akt Signalling Contributes to hSCF Overexpression-induced Cardiac 
Protection after I/R 
To evaluate the molecular mechanism responsible for the effects of cardiac-
specific hSCF overexpression, the PI3K/Akt signaling pathway was studied. Significantly  
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Figure 3.1 Effects of hSCF overexpression on infarct size after I/R.  
Myocardial ischemia was induced by occlusion of the coronary artery for 45 minutes 
followed by 3 hours of reperfusion. Overexpression of hSCF significantly reduced infarct 
size in hSCF/tTA compared to WT mice. Turning off the hSCF expression by DOX 
treatment or inhibition of PI3 kinase by LY294002 abrogated the infarct size decrease in 
hSCF/tTA mice. A: Representative TTC stained heart sections after I/R from each 
corresponding group. B: Infarct size expressed as percent of the weight of the infarct to 
the area at risk. C: Area at risk after I/R. Data are mean ± SEM, n=5-7 per group. Two-
way ANOVA followed by Bonferroni test: *P<0.05 vs I/R; † P<0.05 vs WT. 
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Figure 3.2 Myocardial apoptosis in peri-infarct area after I/R.  
Overexpression of hSCF in hSCF/tTA mice showed significantly less apoptosis as 
measured by caspase-3 activity (A) and cell death ELISA (B). These effects were 
abrogated by turning off the expression of hSCF by DOX treatment or blocking PI3K by 
LY294002 treatment in hSCF/tTA mice. Data are mean ± SEM, n=5. Two-way ANOVA 
followed by Bonferroni test: *P<0.05 vs I/R; † P<0.05 vs WT. 
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higher levels of Akt phosphorylation was observed in hSCF/tTA mice after I/R compare 
to WT (P<0.05, Figure 3.3A), which was abrogated by DOX treatment. Moreover, PI3K 
inhibitor LY294002 abrogated the difference of Akt phosphorylation between hSCF/tTA 
and WT mice after I/R. Interestingly, LY294002 treatment at the dose of 7.5mg/kg 
induced significant impairment of Akt phosphorylation (P<0.05, Figure 3.3B) and 
resulted in significantly higher levels of myocardial apoptosis (Figure 3.2) and larger 
infarct size (Figure 3.1B), suggesting an essential role of PI3K/Akt signaling in cell 
survival after I/R. As one of the important downstream signaling molecules of Akt 
signaling, eNOS activation was also measured. Similarly, higher levels of eNOS 
phosphorylation were found in hSCF/tTA mice after I/R compared to WT (Figure 3.4).  
3.4.3 Overexpression of hSCF Increases c-kit+ Cells in the Myocardium after I/R 
c-kit is the SCF receptor and a surface marker for progenitor/stem cells. 
Accordingly, c-kit immuno-fluorescent staining was performed to analyze the number of 
c-kit+ cells in the heart. A representative image of c-kit+ cells in the myocardium is shown 
in Figure 3.5A. The 2 c-kit+ cells with large circular nuclei and a thin rim of cytoplasm 
are located in the interstitial space of the myocardium. In WT sham hearts, the number of 
c-kit+ cells was about 10 cells per heart section while the number was doubled in 
hSCF/tTA sham hearts (P<0.05, Figure 3.5B). After I/R injury, the number of c-kit+ cells 
was significantly higher in both WT and hSCF/tTA mice while there were significantly 
more c-kit+ cells in hSCF/tTA compared to WT hearts (P<0.05, Figure 3.5B).Consistent 
with these findings, c-kit mRNA levels were significantly upregulated in both WT and  
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Figure 3.3 Myocardial Akt phosphorylation in WT and hSCF/tTA mice after I/R.  
A: Akt phosphorylation was significantly increased in hSCF/tTA compared to WT mice. 
DOX treatment abolished this increase in hSCF/tTA mice. B: Inhibition of PI3K 
significantly lowered Akt phosphorylation both in WT and hSCF/tTA mice. Data are 
mean ± SEM, n=6 per group. Two-way ANOVA followed by Bonferroni test: *P<0.05 
vs I/R groups; † P<0.01 vs WT.  
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Figure 3.4 Myocardial eNOS phosphorylation in WT and hSCF/tTA mice after I/R. 
A: eNOS phosphorylation was significantly higher in the hSCF/tTA mice compared to 
WT. DOX treatment abolished this increase in hSCF/tTA mice. B: Inhibition of PI3K 
with LY294002 significantly impaired eNOS phosphorylation both in WT and hSCF/tTA 
mice. Data are mean ± SEM, n=6 per group. Two-way ANOVA followed by Bonferroni 
test: *P<0.05 vs I/R groups; † P<0.01 vs WT.  
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Figure 3.5 c-kit+ cells in WT and hSCF/tTA hearts.  
A: A representative image of c-kit+ cells in the myocardium. Hoechst (blue, nuclei), c-kit 
(red) and α-actinin (green). B: Quantitative analysis of c-kit+ cells in heart sections. The 
population of c-kit+ cells was significantly higher in both WT and hSCF/tTA hearts after 
I/R. However, there were significantly more c-kit+ cells in hSCF/tTA compared to WT 
mice after I/R, which was abrogated by blocking c-kit signalling using ACK2. C: 
Myocardial c-kit mRNA expression was significantly higher in hSCF/tTA compared to 
WT mice after I/R. Blockade of c-kit signalling by ACK2 abrogated this effect. D: 
Quantitative analysis of Ki67+ cells in the heart of WT and hSCF/tTA mice showed no 
difference between the two groups (unpaired Student t-test, P=n.s). E: Blockade of c-kit 
signalling by ACK2 or Crizotinib treatment abolished the reduction of infarct size in 
hSCF/tTA mice after I/R. Note: The same I/R groups from Figure 3.1B were used in this 
graph. Data are mean ± SEM, n=5-7. Two-way ANOVA followed by Bonferroni test: 
*P<0.05 vs Sham, † P<0.05 vs WT. 
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hSCF/tTA mice after I/R. Furthermore, myocardial c-kit mRNA levels were significantly 
higher in hSCF/tTA compared to WT mice after I/R (Figure 3.5C). However, cell 
proliferation in the myocardium after I/R assessed by Ki67 staining did not show any 
significant difference between WT and hSCF/tTA mice (Figure 3.5D). Finally, c-kit 
neutralizing antibody ACK2 was used to further investigate the role of c-kit signalling in 
the cardioprotection of hSCF overexpression after I/R. Inhibition of c-kit function by 
ACK2 not only abrogated increases in the number of c-kit+ cells in the heart (Figure 
3.5B) but also abolished the reduction of infarct size in hSCF/tTA mice after I/R (P<0.05, 
Figure 3.5E).  
3.4.4 Overexpression of hSCF Enhances Protective Growth Factor Expression 
after I/R 
Previous studies have implicated growth factors including HGF and IGF-1 in 
promoting cardiomyocyte survival after I/R.7,26 Production of these growth factors by 
stem cells supports the paracrine effects of stem cell therapy in ischemic heart 
disease.27,28 To determine the expression levels of these growth factors, real-time RT-
PCR and western blot analysis was employed. HGF and IGF-1 mRNA and protein 
expression was significantly increased after I/R in both WT and hSCF/tTA mice (P<0.05, 
Figure 3.6). However, significantly higher HGF and IGF-1 expression were observed in 
hSCF/tTA compared to WT hearts (P<0.05, Figure 3.6). Blocking c-kit signaling by 
ACK2 abolished the enhanced HGF and IGF-1 expression in the hSCF/tTA heart after 
I/R (P<0.05, Figure 3.6). To further demonstrate the role of HGF in cardioprotection by 
hSCF overexpression, an inhibitor of HGF receptor crizotinib was used. Treatment with  
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Figure 3.6 Cardioprotective cytokine expression in WT and hSCF/tTA mice after 
I/R.  
Expression of HGF and IGF-1 mRNA was detected by real-time RT-PCR. After I/R, 
HGF and IGF-1 expression was significantly upregulated both in WT and hSCF/tTA 
mice. However, a significantly higher level of HGF and IGF-1 expression was found in 
hSCF/tTA mice compared to WT. This increase was abrogated by ACK2 treatment. Data 
are mean ± SEM, n=6; Two-way ANOVA followed by Bonferroni test: *P<0.05 vs 
Sham; † P<0.05 vs WT. 
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crizotinib (15 mg/kg, IP) abolished the reduction in infarct size after I/R in hSCF/tTA 
mice with no significant effect in WT mice (Figure 3.5E). 
3.4.5 Sub-population of c-kit+ Cells in Hearts with hSCF Overexpression after I/R 
c-kit is a reliable marker for cardiac progenitors and circulating stem cells.13,29 
Moreover, hematopoietic mast cells (CD45+) are also positive for c-kit. In order to further 
investigate the source of increased c-kit+ cells in hSCF/tTA hearts after I/R, CD45 was 
used to distinguish the c-kit+ cell sub-populations.  Representative images of CD45+c-kit+ 
and CD45-c-kit+ cells are shown in Figure 3.7A. CD45-c-kit+ cells are identified as 
cardiac stem cells capable of cardiogenesis.12,13 Our data show that in sham and I/R 
groups, the numbers of CD45-c-kit+ cells in hSCF/tTA myocardium were significantly 
higher compared to WT (P<0.05, Figure 3.7B). Moreover, an endogenous increase in 
CSCs after I/R was observed in the peri-and non-infarct area of WT myocardium 
(P<0.05, Figure 3.7C), which was further enhanced in hSCF/tTA mice (P<0.05, Figure 
3.7C). On the other hand, a significantly higher populations of  CD45+c-kit+ cells were 
found in both hSCF/tTA and WT hearts after I/R compared to sham, while there were 
more CD45+ c-kit+ cells retained in the hSCF/tTA compared to WT  myocardium 
(P<0.05, Figure 3.7D). Interestingly, the number of mast cells determined by toluidine 
blue staining after I/R was similar between WT and hSCF/tTA hearts, suggesting that 
mast cells do not contribute to the increases of c-kit+ cell population induced by hSCF 
overexpression (Figure 3.7E).  
145 
 
Figure 3.7 Sub-population of c-kit+ cells in the myocardium after I/R.  
A: A representative image of CD45+c-kit+ cells and CD45-c-kit+cells in the myocardium. 
Hoechst (blue, nuclei), c-kit (red) and CD45 (green). B: Quantitative analysis shows there 
were significantly more CD45-c-kit+ cells in hSCF/tTA compared to WT hearts in sham 
and I/R groups. C: In peri-and non-infarct area, more CD45-c-kit+ cells were observed in 
both WT and hSCF/tTA mice after I/R compared to sham groups while the population of  
CD45-c-kit+ cells was higher in hSCF/tTA mice compared to WT after I/R.  D: CD45+c-
kit+ cell number was significantly higher in hSCF/tTA mice compared to WT after I/R.  
E: Quantification of mast cells detected by toluidine blue showed no significant 
difference between WT and hSCF/tTA mice. Two-way ANOVA followed by Bonferroni 
test: *P<0.05 vs Sham; † P<0.05 vs WT. 
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3.4.6 Overexpression of hSCF enhances CSC proliferation and HGF expression in 
vitro 
In order to further investigate the effects of hSCF overexpression on CSC activity, 
c-kit+ CSCs were isolated and cultured in vitro. Flow cytometry analysis showed the 
isolated c-kit+ CSCs were negative for CD45 (Figure 3.8A). HGF mRNA expression 
was also higher in the Ad-hSCF group compared to the Ad-LacZ (Figure 3.8B). No 
difference in IGF-1 expression was found between groups (Figure 3.8C).   
3.5 DISCUSSION 
              The present study demonstrates that cardiomyocyte-specific overexpression of 
hSCF reduces myocardial apoptosis and infarct size after acute myocardial I/R. When 
hSCF expression was turned off by DOX treatment, these effects were abrogated, which 
clearly implies that overexpression of hSCF is responsible for the cardiac protection in 
I/R. Our novel findings are: 1) hSCF overexpression reduces myocardial apoptosis and 
infarct size via Akt-PI3K signaling pathway. 2) SCF/c-kit signaling is responsible for the 
reduced infarct size and enhanced growth factor (IGF-1 and HGF) expression in the 
hSCF overexpressing myocardium after I/R, and 3) overexpression of hSCF increases 
endogenous CSCs activation after I/R. Our study suggests that hSCF may have 
therapeutic potential in the treatment of ischemic heart disease. 
In acute myocardial I/R, the lack of blood supply during ischemia and the 
oxidative stress followed by abrupt metabolic changes immediately after reperfusion 
leads to severe cellular injuries.30 It is widely accepted that both necrosis and apoptotic  
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Figure 3.8 Overexpression of hSCF in c-kit+ CSCs in vitro.  
A: Flow cytometry analysis showed no CD45 expression in c-kit+ CSCs. B: HGF mRNA 
expression was enhanced in hSCF overexpressing CSCs, which was abrogated by ACK2 
treatment. C: No difference of IGF-1 mRNA expression was observed between groups. 
Two-way ANOVA followed by Bonferroni test: *P<0.05 vs Sham; † P<0.05 vs WT. 
149 
 
150 
 
cell death contribute to infarct size development and cell loss during I/R.31 Apoptosis 
differs from necrosis in that it is a finely regulated process initiated by the cell itself.31 
Interventions that suppress myocardial apoptosis during I/R decrease infarct size and 
improve cardiac function.32,33 In the present study, we found that cardiac-specific 
overexpression of hSCF decreased infarct size and myocardial apoptosis after I/R. 
Moreover, the fact that reduction in infarct size was completely abolished when hSCF 
overexpression was turned off further confirmed the beneficial effects are due to hSCF 
overexpression in the myocardium. The signaling pathway responsible for the 
improvement was further investigated. As the major component of the reperfusion injury 
salvage kinase pathway (RISK),3 PI3K/Akt/eNOS signaling was increased in hSCF 
overexpressing hearts after I/R. Blocking PI3K-Akt signaling by LY294002 abrogated 
Akt/eNOS activation and increased myocardial apoptosis and infarct size, which clearly 
demonstrate that PI3K/Akt/eNOS signaling is responsible for the cardiac protection in 
hearts with hSCF overexpression after I/R.  
The activation of RISK pathway can be induced by cardiac protective growth 
factors during I/R 7. In this regard, exogenous administration of IGF-134 and HGF 26,35,36  
has been shown to decrease myocardial apoptosis and infarct size in acute I/R injury. As 
an endogenous response, the heart is also able to produce cardioprotective growth factors 
after ischemia. In our study, acute I/R induced HGF and IGF-1 expression in the WT 
myocardium, which is consistent with previous studies in the porcine I/R model.37 This 
endogenous protective mechanism in acute I/R by releasing beneficial growth factors is 
further enhanced by hSCF overexpression. Inhibition of HGF receptor signaling 
abrogated the improved infarct size in hSCF overexpressing mice after I/R, suggesting 
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that HGF contributes to the protective effects of hSCF overexpression. More importantly, 
our study provided convincing evidence that SCF/c-kit signaling plays a critical role in 
this process as the higher expression of HGF and IGF-1 was abolished by ACK2 
treatment in mice with hSCF overexpression.  
               It is now recognized that mechanisms of cardiac protection from endogenous 
stem/progenitor cell recruitment and/or exogenous stem cell delivery may include 
paracrine effects,38  which result from the secretion of various cytokines, chemokines and 
growth factors, and possibly by their direct differentiation into cardiomyocytes 39 and 
vascular cells. Despite the significant beneficial effects observed in animal models, 
clinical trials using bone marrow stem cells only showed minor improvement in MI 
patients.40 The key issues to be resolved include choosing the optimal stem cell type, 29,41 
safe and efficient delivery method 39 and maximizing cell retention and engraftment.42  
Mobilization of hematopoietic and endothelial progenitors to the peripheral blood occurs 
within a few hours after acute MI, acting as an endogenous response to tissue damage.43 
Our efforts have been focused on enhancement of the endogenous recruitment to and 
retention of the stem/progenitor cells in the ischemic myocardium. The previous chapter 
showed hSCF overexpression increases EPC recruitment and retention in myocardium 5 
days post-MI. In this chapter, a significant increase of c-kit+ cell numbers in the WT 
myocardium after acute I/R compared to that of sham mice was observed, which is an 
endogenous response to myocardial ischemia. By overexpressing hSCF in 
cardiomyocytes, we showed for the first time that the c-kit+ cell population was further 
increased after acute I/R compared to WT. Furthermore, when the SCF/c-kit signaling 
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was blocked by ACK2, the increase of c-kit+ cells induced by hSCF overexpression after 
I/R was abrogated, illustrating a critical role of SCF/c-kit interaction in this process.        
            The c-kit+ cells in the adult heart have 2 sub-populations, CD45-c-kit+ and 
CD45+c-kit+ cells. The CD45-c-kit+ cells are endogenous CSCs which are able to 
differentiate into cardiomyocytes.12,39 The increase of CSCs is observed several days after 
acute MI and contributes to myocardial repair.44 In the present study we showed that the 
number of CSCs was increased in the upper half of the heart, which was mainly non-
infarct area of the myocardium after I/R, and was further enhanced by hSCF 
overexpression. The increase in c-kit+ cell population induced by hSCF overexpression is 
possibly due to cell migration and recruitment from CSC niches or the circulation since 
cell proliferation assessed by Ki67 staining did not show a significant difference between 
WT and hSCF overexpressing mice after I/R. Interestingly, under basal conditions, more 
CSCs were found in hSCF overexpression myocardium compared to the WT, which 
suggests a pivotal role of membrane-associated SCF in maintaining a CSC pool in the 
myocardium of the adult heart. Despite increases in number, CSCs in the hSCF 
overexpression heart remain quiescent until an ischemic insult occurs, which is confirmed 
by the finding that the expression of HGF and IGF-1 is not increased in hSCF 
overexpressing mice under basal conditions.The effects of hSCF on CSC activity were 
further studied in isolated c-kit+ CSCs in vitro. Overexpression of hSCF enhanced HGF 
expression in CSCs via c-kit signaling. 
On the other hand, our study also showed significantly more CD45+c-kit+ cells in 
the heart after I/R. Moreover, hSCF overexpression resulted in a 1.7 fold higher CD45+c-
kit+ cells compared to WT mice after I/R. The CD45+c-kit+ cells are of hematopoietic 
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lineage which includes mast cells, circulating hematopoietic stem cells 45 and endothelial 
progenitors.46 We first confirmed that the increase of CD45+c-kit+ cells was not due to 
mast cells recruitment through toluidine blue staining. No significant difference in the 
number of mast cells was observed between WT and hSCF overexpressing mice after I/R. 
Thus, the higher number of CD45+c-kit+ cells suggests hSCF overexpression promotes 
recruitment of circulating progenitor cells after I/R. These data are consistent with 
previous findings from our lab and others that interaction of membrane-associated SCF 
and c-kit enhances circulating c-kit+ progenitor recruitment.47  
In conclusion, our data show that cardiomyocyte-specific hSCF overexpression 
reduces infarct size and myocardial apoptosis after acute I/R. These beneficial effects are 
likely due to enhanced activation of PI3K/Akt/eNOS signaling and production of 
cardioprotective growth factors induced by increased population of c-kit+ progenitors in 
the ischemic myocardium. The capability of M-SCF to provide cardioprotection in both 
acute I/R and chronic heart failure makes it a promising candidate as a new treatment for 
ischemic heart disease.   
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4 CHAPTER 4 
Cardiac-Specific Overexpression of Human Stem Cell Factor Promotes Epicardial 
Activation and Arteriogenesis after Myocardial Infarction 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been submitted to Circulation Heart Failure.: 
Xiang F, Lu X, Liu Y, Feng Q  
“Cardiac-Specific Overexpression of Human Stem Cell Factor Promotes Epicardial 
Activation and Arteriogenesis after Myocardial Infarction.”  
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4.1 CHAPTER SUMMARY 
In Chapters 2 and 3, I showed that cardiomyocyte-specific overexpression of 
hSCF protects the heart from ischemic injury via regulating the activities of c-kit+ 
stem/progenitor cells, such as EPCs and CSCs. Recent studies have shown that the adult 
epicardium is also a potential source of cardiac progenitors following MI. In this chapter, 
I investigated the effects of cardiomyocyte-specific overexpression of hSCF on epicardial 
activation post-MI. I found that hSCF overexpression promoted epicardial activation and 
arteriogenesis post-MI. These cardioprotective effects were related to increased EPDC 
production, proliferation and migration. Furthermore, lineage tracing of Wt1 EPDCs 
showed convincing evidence that EPDCs were activated and able to migrate into the 
infarcted myocardium post-MI, which was further enhanced by hSCF overexpression. In 
conclusion, cardiomyocyte-specific overexpression of hSCF promotes epicardial 
activation, EPDC production, proliferation and migration, which contributes to 
arteriogenesis post-MI. 
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4.2 INTRODUCTION 
Cardiovascular disease remains a leading cause of death worldwide.1 In the past 
decade, adult stem cell therapy has emerged as a promising new strategy for ischemic 
heart disease.2 To this end, both  cardiac and extra-cardiac progenitor cells have been 
demonstrated to improve cardiac function after myocardial infarction (MI).2 The 
epicardium-derived cells (EPDCs) are cardiac progenitors that contribute to coronary 
artery formation during embryonic heart development.3-5 Recent studies have shown that 
transplantation of adult EPDCs into the ischemic myocardium in mice preserves cardiac 
function and attenuates ventricular remodeling via enhancement of neovascularization, 
suggesting their therapeutic potential in cardiac repair post-MI.6   
During early heart morphogenesis, cells from the proepicardial organ migrate to 
the looping heart tube to form the epicardium.7 A fraction of these cells undergoes 
epithelial to mesenchymal transition (EMT), invades into the myocardium and becomes 
EPDCs, which give rise to smooth muscle cells, perivascular and interstitial fibroblasts, 
and form coronary arteries with contributions from the endocardium and sinus venosus.8-
11
 Wilms tumor-1 (Wt1) is expressed in the EPDCs and promotes EMT 12 while its 
expression is turned off in fully differentiated EPDCs.13-15 The adult epicardium is 
inactive under normal physiological conditions, but can be re-activated and produces 
EPDCs after MI. Some of the EPDCs also express c-kit.16,17 However, the number of 
endogenously generated EPDCs is not sufficient for adequate cardiac repair post-MI. 
Measures that promote epicardial activation and EPDC production may enhance cardiac 
repair post-MI.  
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Stem cell factor (SCF) binds to c-kit and promotes survival, proliferation, 
mobilization, and adhesion of all c-kit-expressing cells.18 Alternative splicing leads to 
two isoforms of SCF, the soluble and membrane-associated isoforms, which differ in the 
absence or presence of a proteolytic cleavage site encoded by exon 6.19 The membrane-
associated SCF is the dominant isoform in vivo and induces more persistent and long-
term support of target cell survival. However, the effects of SCF on epicardial activation 
post-MI are not known. In the present study, we hypothesized that inducible 
cardiomyocyte-specific overexpression of membrane-associated human stem cell factor 
(hSCF) promotes epicardial activation and EPDC production post-MI. To test this 
hypothesis, mice with cardiomyocyte-specific overexpression of hSCF were subjected to 
coronary artery ligation to induce MI. Epicardial Wt1 expression, myocardial growth 
factor levels and arteriole density were studied. Furthermore, cell fate of Wt1 expressing 
epicardial cells post-MI was determined using lineage tracing. Our results demonstrated 
that cardiomyocyte-specific overexpression of hSCF enhances epicardial activation and 
arteriogenesis post-MI.   
 
4.3 METHODS 
4.3.1 Animals 
Animals in this study were handled in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institute of Health (NIH 
publication No. 85-23, revised 1996) and animal handling was approved by the Animal 
Use Subcommittee at the University of Western Ontario, Canada. The conditional 
cardiac-specific hSCF overexpressing hSCF/tTA transgenic mice were generated using α-
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MHC promoter as described in Chapter 2. In the doxycycline (DOX) group, mice were 
treated with DOX (0.2 mg/ml in drinking water) to turn off hSCF overexpression starting 
from 2 weeks before the surgeries. The mTmG (membrane-Tomato/membrane-Green) 
targeted-Rosa26 mice (stock #7576) and Wt1CreER mice (Stock # 010912) were purchased 
from Jackson Laboratory and bred to generate ROSAmTmG;Wt1CreER mice. Tamoxifen (40 
mg/kg, i.p.) treatment was performed for 5 days before surgery to trace the lineage of 
Wt1+ cell derived EPDCs in the myocardium post-MI. To inhibit c-kit function, mice 
were injected intraperitoneally with 100 µg c-kit neutralizing antibody ACK2 (a gift from 
Dr. Shin-Ichi Nishikawa, Kyoto University, Kyoto, Japan) per day post-MI.20,21 In total, 
68 WT, 68 hSCF/tTA and 24 ROSAmTmG;Wt1CreER  mice were used for in vivo 
experiments. Each EPDC culture was from 12-16 hearts of P0 or E13.5 mice. 
4.3.2 MI Mouse Model 
MI was induced by occlusion of the left main coronary artery. Briefly, mice were 
anesthetized with a ketamine (50 mg/kg) and xylazine (12.5 mg/kg) cocktail (i.m.), 
intubated and artificially ventilated. The adequacy of anesthesia was monitored by 
absence of withdrawal reflex to tail pinch. Subsequently, a left intercostal thoracotomy 
was performed and the left coronary artery was surgically ligated. To achieve in vivo 
adenoviral infection, 107 transducing units of adenoviral vector expressing recombinant 
hSCF (Ad-hSCF) or LacZ (Ad-LacZ) in 5µL saline was injected into 3-5 sites of the peri-
infarct myocardium immediately after coronary artery ligation. The infection efficiency 
was confirmed by western blot analysis. 
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4.3.3 EPDC Culture  
EPDCs were cultured as previously described.22,23 Hearts were removed from 
postnatal day 0 (P0) or embryonic day 13.5 (E13.5)  mice, cut into pieces, rinsed in PBS 
to remove excess blood and plated onto  1% gelatin-coated culture dish (epicardial side 
facing down) in DMEM containing GlutaMaxTM, 4.5 g/L glucose, 1% penicillin and 
streptomycin, and 15% fetal calf serum  for 6-9 days. EPDCs which had migrated from 
the heart explants were utilized for further experiments. First passage EPDCs were 
employed in EPDC proliferation experiments. Each well of a 24-well plate was seeded 
with 104 EPDCs. Ad-hSCF or Ad-GFP was added at a concentration of 10 MOI 
(multiplicity of infection). After 24 hours, cells were trypsinized and counted by 
NucleoCounter (New Brunswick Scientific, Enfield, CT, USA).  
4.3.4 Neonatal Cardiomyocyte Culture  
P0 mice were sacrificed by cervical dislocation without anesthesia. Hearts were 
isolated, cardiomyocytes were obtained and cultured in 24 well plates according to 
methods we previously described.24,25 Overexpression of hSCF in WT neonatal 
cardiomyocytes was accomplished through the adenoviral infection of Ad-hSCF. Viral 
vectors containing LacZ served as controls. Cells were infected with adenoviruses at an 
MOI of 10 and incubated for 2 hours in the presence of 200µl of M199 with 2% FCS. 
Following the 2 hour incubation, 800µl of 10% FCS M199 was applied. Cells were 
incubated for an additional 48 h and utilized for further experiments. 
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4.3.5 Transwell Migration Assay  
A transwell system was employed to investigate EPDC migration. Neonatal 
cardiomyocytes infected with Ad-hSCF or Ad-LacZ were cultured in the basal 
compartment. First passage GFP+ EPDCs (5x104) were subcultured in transwell cell 
culture inserts (8-µm diameter pores, Becton Dickinson Labware, Franklin Lakes, NJ, 
USA). After incubation for 24 hour at 37oC and 5% CO2, the cells on upper layer of the 
insert membrane were completely removed using a cotton swab. GFP+ EPDCs which had 
migrated to the other side of membrane were imaged by a fluorescent microscope 
(Observer D1, Carl Zeiss Canada, Toronto, Canada) and quantified. 
4.3.6 Real-time RT-PCR 
Total mRNA was isolated with TRIzol reagent (Invitrogen, Grand Island, NY, 
USA) as previously described in Chapter 2. cDNA was synthesized using Moloney 
murine leukemia virus reverse transcriptase and random primers. Real-time PCR was 
conducted using SYBR Green PCR Master Mix (Eurogentec, San Diego, CA, USA). 28S 
rRNA was used as a loading control. The oligonucleotide primer sequences were as 
follows: TGF-β1, forward, CAC TGC TTC CCG AAT GTC TG, reverse, GCC CGA 
AGC GGA CTA CTA TG; soluble mouse SCF (include exon 6), forward, GCT TTG 
CTT TTG GAG CCT TA reverse, TGA AAT TCT CTC TCT TTC TGT T; VEGF-A, 
forward, GAT TGA GAC CCT GGT GGA CAT C, reverse, TCT CCT ATG TGC TGG CTT 
TGG T; bFGF, forward, CAA GGG AGT GTG TGC CAA CC, reverse, TGC CCA GTT 
CGT TTC AGT GC. Samples were amplified for 35 cycles using an Eppendorf 
Mastercycler Real-Time PCR machine (Eppendorf, Hamburg, Germany).  The mRNA 
levels in relation to 28S rRNA were determined using a comparative Ct method. 
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4.3.7 Immunohistochemistry  
Paraffin sections of the heart were deparaffinized, hydrated and rinsed in PBS. 
Antigen retrieval was performed by microwaving the slides in 10mM sodium citrate 
buffer (PH6.0) for 10 minutes. After serum blocking, slides were incubated with primary 
antibodies followed by biotinylated secondary antibody. Color development was carried 
out after incubation using an ABC kit (Vector Laboratory, Burlingame, CA, USA) and 
then developed with DAB solution. Nuclei were counterstained with hematoxylin. 
Epicardial Wt1+ cells were quantified and these data are presented as cell number per mm 
of epicardium. Frozen tissue sections and cover glasses with cells adhering on the surface 
were fixed in 4% paraformaldehyde. Endogenous fluorescence was bleached by 
incubation in 0.3% H2O2 overnight in a UV box.12 Primary antibodies and fluorescent 
second antibodies were then applied. For fluorescent visualization, nuclei were stained 
with Hoechst reagent. Representative images were taken using a fluorescent microscope 
(Observer D1, Carl Zeiss Canada, Toronto, Canada). Primary antibody used includes: 
Wilms tumor 1 (Wt1, 1:300, Calbiochem, San Diego, CA, USA), phosphorylated Smad2 
(p-Smad2, 1:200, Cell Signaling Technology, Danvers, MA, USA), smooth muscle actin 
(SMA, 1:1000, Sigma, St Louis, MO, USA), green fluorescent protein (GFP, 1:2000, 
Abcam, Cambridge, MA, USA), epicardin (1:300, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), c-kit (1:300, Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Quantification of epicardial Wt1+ cells was presented by epicardial Wt1+ cell number 
divided by the length of epicardium. 
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4.3.8 Western Blot Analysis  
Expression of hSCF after Ad-hSCF adenoviral infection was measured by western 
blot analysis. Briefly, 40 µg of protein were separated by 12% SDS-PAGE gel and 
transferred to nitrocellulose membranes, and blots were probed with antibodies against 
hSCF (1:500, Abcam, Cambridge, MA, USA) or α-actinin (1:2500, Sigma, St Louis, MO, 
USA). Blots were then washed and probed with horseradish peroxidase conjugated 
secondary antibodies (1:3000, Bio-Rad, Hercules, CA, USA), and detected by using an 
ECL detection method.  
4.3.9   Statistical Analysis 
Data are expressed as the mean ± SEM. Two-way ANOVA followed by 
Bonferroni test was performed for multiple group comparisons. Unpaired Student t-test 
was used for two group comparisons. Differences were considered statistically significant 
at the level of P<0.05.  
4.4 Results 
4.4.1 Epicardial Activation 3 Days post-MI  
WT and hSCF/tTA mice were subjected to either coronary artery ligation to 
induce MI or sham surgery. Three days after surgery, animals were sacrificed and heart 
sections were immunostained for Wt1, a specific marker for EPDC activation (Figure 
4.1A). Wt1+ cells in the epicardium were quantified. Few if any Wt1+ cells were found in 
the epicardium of sham groups. Three days post-MI, Wt1+ cells in the epicardium of the 
infarct area (including peri-infarct area) were increased in both WT and hSCF/tTA mice. 
Because Wt1 expression in EPDCs is turned off shortly after EMT, 26 it is not surprising 
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Figure 4.1 Epicardial Wt1 expression 3 days post-MI.  
(A) Representative images for Wt1 staining. a: Wt1 positive cells show dark brown 
nuclear staining. Arrow heads point to Wt1 positive cell in the epicardium. (B) 
Quantification of Wt1 positive cells in the epicardium. In the epicardium of infarct and 
peri-infarct area, significantly more epicardial Wt1+ cells were observed in hSCF/tTA 
compared to WT mice 3 days post-MI. This was abrogated by DOX and ACK2 
treatment. In the non-infarct area, epicardial activation was also detected. Two-way 
ANOVA followed by Bonferroni test: *P<0.05 vs WT. (C) Overexpression of hSCF 
showed significantly higher TGFβ mRNA expression in hSCF/tTA mice compared to 
WT post-MI. This was abrogated by ACK2 treatment. (D) Representative images of Wt1 
and p-Smad2 staining in epicardium of WT and hSCF/tTA mice 3 days post-MI. White 
dash line labels the boundary of the epicardium. Smad2 activation was observed in all the 
epicardial Wt1+ cells. Two-way ANOVA followed by Bonferroni test: *P<0.05 vs Sham, 
† P<0.05 vs WT. Data are mean ± SEM, n=5-7 
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that very few Wt1+ cells were observed in the myocardium. However, the population of 
epicardial Wt1+ cells in hSCF/tTA mice was almost doubled in the infarct area compared 
to WT (P<0.05, Figure 4.1B). Interestingly, treatment with either DOX to turn off hSCF 
expression or ACK2 to block the SCF/c-kit signaling, abrogated this response. The 
number of epicardial Wt1+ cells was similar in the non-infarct area between hSCF/tTA 
and WT mice.  
TGFβ1 is a key regulator of the EMT process. To assess its expression, TGFβ1 
mRNA levels in the epicardium and subepicardial area were determined by real-time RT-
PCR. Consistent with previous studies,27,28 we found expression of TGFβ1 mRNA was 
significantly higher post-MI compared to sham groups (P<0.05, Figure 4.1C). Our data 
further showed that TGFβ1 mRNA levels of epicardial and subepicardial tissues were 
significantly higher in the peri-infarct area of hSCF/tTA compared to WT mice, and the 
response was abolished by either DOX or ACK2 treatment (P<0.05, Figure 4.1C). As 
expected, in the Wt1+ epicardial cells 3 days post-MI, Smad2 was also activated 
indicating the activation of TGFβ1 signaling in those cells (Figure 4.1D).     
4.4.2 Arteriolar Density in the Peri-infarct Area 5 Days post-MI  
EPDCs are essential for coronary artery formation during embryonic 
development.26 To investigate the effects of enhanced epicardial activation on coronary 
artery formation post-MI, SMA staining was employed to stain smooth muscle cells and 
the number of arterioles (between 15-150 µm) in the peri-infarct area was quantified. 
Representative photomicrographs of SMA staining are presented in Figure 4.2A. Each 
arrow points to an arteriole. Five days post-MI, arteriole density in the peri-infarct area 
was significantly higher in hSCF/tTA compared to WT mice (P<0.05, Figure 4.2B). 
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Figure 4.2 Arteriolar density in the peri-infarct area 5 days post-MI.  
(A) Representative images of α-SMA staining. Arterioles were identified as small vessels 
surrounded by SMA positive cells. Arrows point at arterioles. (B) Quantification of 
arteriole density. Number of arterioles was significantly higher in the peri-infarct area of 
hSCF/tTA compared to WT mice 5 days post-MI. This increase was abrogated by DOX 
and ACK2 treatment. Data are mean ± SEM, n=5. Two-way ANOVA followed by 
Bonferroni test: *P<0.05 vs WT. 
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Furthermore, the response was abrogated by DOX or ACK2 treatment (P<0.05, Figure 
4.2B), suggesting SCF/c-kit signaling promotes myocardial arteriogenesis post-MI.  
4.4.3 Outgrowth of Cultured EPDCs  
EPDCs can grow out from P0 or E13.5 heart explant cultures and form a 
monolayer of cobblestone shaped cells (Figure 4.3A). The purity of EPDCs was 
confirmed by detecting EPDC specific marker expression (Figure 4.3B). To study the 
effects of SCF on the outgrowth of EPDCs, heart tissue sections from P0 WT mice were 
cultured and randomly divided into 2 treatment groups: control or recombinant mouse 
SCF (100 ng/mL). Six days after culturing, outgrowth of EPDCs from the heart tissue 
was observed (Figure 4.4A). Treatment with recombinant mouse SCF resulted in a 
significantly more robust EPDC outgrowth compared to controls (P<0.05, Figure 4.4B). 
Proliferation and Pro-angiogenic Growth Factor Expression of Cultured EPDCs 
To assess EPDC proliferation, E13.5 mice were obtained through timed breeding. 
Cultured EPDCs isolated from E13.5 and P0 hearts of WT mice were treated with Ad-
hSCF. The expression of hSCF protein after Ad-hSCF infection was confirmed by 
western blot analysis (Figure 4.5).  After 24 hours of treatment, EPDC cell numbers were 
significantly higher in the Ad-hSCF group compared to Ad-GFP control group (P<0.05, 
Figure 4.4C and D). Treatment with ACK2 showed significantly lower EPDC cell 
numbers in both Ad-hSCF and Ad-GFP groups (P<0.05, Figure 4.4C and D). 
To investigate pro-angiogenic growth factor expression, cultured EPDCs from P0 
hearts of WT mice were treated with Ad-GFP or Ad-hSCF for 24 hours. VEGF-A and 
bFGF mRNA levels were significantly higher in the Ad-hSCF group compared to Ad-
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Figure 4.3 In vitro culture of EPDCs.  
(A): Six days after heart explant culture, a cobblestone shaped cell monolayer was 
observed surrounding the heart explants. (B): Cobblestone shaped cells outgrown from 
the heart explants were 100% positive for epicardin (nuclear: blue, epicardin: red) and 
Wt1 (nuclear: blue, Wt1: red). Some EPDCs were also positive for c-kit (nuclear: blue, c-
kit: red). 
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Figure 4.4 Outgrowth, proliferation and growth factor expression in cultured 
EPDCs.  
(A) Representative images showing EPDC outgrowth from the P0 heart explants (H). 
Arrows indicate the EPDC migration distance from the heart explants. (B) Recombinant 
human stem cell factor treatment (100 ng/ml) significantly enhanced EPDC outgrowth 
compared to control (n=7 per group). Unpaired Student’s t test: *P<0.05 vs Control. (C 
and D) Overexpression of hSCF by Ad-hSCF infection significantly enhanced 
proliferation of E13.5 (C) and P0 (D) EPDCs compared to the Ad-GFP control group. 
ACK2 treatment significantly impaired EPDC proliferation in both groups. (E and F) 
VEGF-A and bFGF mRNA levels in P0 EPDCs detected by real-time RT-PCR were 
significantly higher in Ad-hSCF treatment compared to Ad-GFP. This effect was 
abolished by ACK2. Data are mean ± SEM, n=4. One-way ANOVA followed by 
Bonferroni test: *P<0.05 vs Ad-GFP, † P<0.05 vs Ad-hSCF. 
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Figure 4.5 Expression of hSCF protein in adenovirus treated EPDCs.  
Cultured EPDCs treated with Ad-hSCF or Ad-LacZ were subjected to western blot 
analysis. Expression of hSCF protein was observed only in Ad-hSCF infected EPDCs.
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GFP control group (P<0.05, Figure 4.4E and F). Treatment with ACK2 abrogated this 
effect (Figure 4.4E and F). 
4.4.4 Migration of Cultured EPDCs 
A transwell assay was employed to study the effect of hSCF overexpression on 
EPDC migration. EPDCs were isolated from GFP transgenic mice and seeded on the 
upper inserts with 8 µm pores. Neonatal cardiomyocytes infected with either Ad-LacZ or 
Ad-hSCF were seeded on the lower chamber. Cells were allowed to migrate for 24 hours 
and the number of GFP+ EPDCs which had migrated through the insert membrane were 
detected using fluorescence microscopy. As shown in Figure 4.6A, the green cells are 
GFP+ EPDCs migrated through the membrane. Quantitative analysis showed that Ad-
hSCF significantly enhanced EPDC migration compared to Ad-LacZ (P<0.05, Figure 
4.6B).  
Furthermore, inhibition of c-kit signaling by ACK2 significantly attenuated EPDC 
migration in both Ad-LacZ and Ad-hSCF treatment groups (P<0.05, Figure 4.6B). The 
data implies that EPDC migration is enhanced by chemokine release from the Ad-hSCF 
treated cardiomyocytes in the lower chamber. This effect is likely mediated by autocrine 
SCF production as soluble mouse SCF expression was significantly higher in hSCF 
overexpressing cardiomyocytes and lower with ACK2 treatment (P<0.05, Figure 4.6C), 
suggesting SCF/c-kit signaling is involved in EPDC migration. 
4.4.5 Lineage Tracing of Wt1+ EPDCs 
EPDC activation and migration into the myocardium post-MI was further 
investigated by lineage tracing of Wt1+ EPDCs. Cre activation was induced by tamoxifen 
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Figure 4.6 Transwell EPDC migration.  
(A) Representative images of GFP+ EPDCs which had migrated through the membrane. 
(B) Quantification of GFP+ EPDCs which had migrated through the membrane. Number 
of GFP+ EPDCs which had migrated to the lower surface of the membrane was 
significantly higher in Ad-hSCF treated group compared to the Ad-LacZ. The migration 
was significantly inhibited by ACK2 treatment. (C) Expression level of soluble mouse 
SCF mRNA was significantly higher in Ad-hSCF treated neonatal cardiomyocytes 
compared to the Ad-LacZ group. The response was inhibited by ACK2. Data are mean ± 
SEM, n=3. One-way ANOVA followed by Bonferroni test: *P<0.05 vs Ad-LacZ, † 
P<0.05 vs Ad-hSCF 
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injection for 5 days before MI in ROSAmTmG;Wt1CreER mice (Figure 4.7A). Fluorescent 
staining of GFP and Wt1 confirmed the success of the inducible lineage tracing system. 
Five days post-MI, 70-80% of the Wt1+ cells expressed GFP while all GFP+ cells in the 
epicardium were Wt1+. Myocardial overexpression of hSCF in ROSAmTmG;Wt1CreER mice 
was induced by intra-myocardial injection of Ad-hSCF in the peri-infarct area 
immediately following coronary artery ligation. The expression of hSCF protein in the 
peri-infarct area 5 days post-MI was detected by western blot (Figure 4.8). GFP+ cells 
representing EPDCs derived from Wt1 expressing cells were found in the epicardium 5 
days post-MI (Figure 4.7B), which is consistent with our findings in Figure 4.1A and B. 
Importantly, GFP+ cells were also observed in the infarcted myocardium (Figure 4.7C), 
providing direct evidence that Wt1+ EPDCs were activated and migrated into the infarct 
area. Furthermore, treatment with Ad-hSCF induced significantly more GFP+ cells in the 
epicardium and infarcted myocardium compared to Ad-LacZ (P<0.05, Figure 4.7D and 
E), which was abrogated by ACK2. Additionally, higher myocardial expression of TGFβ, 
a key factor in promoting EMT, was detected in Ad-hSCF group compared to Ad-LacZ 
and this effect was also abrogated by ACK2 treatment (Figure 4.7F). 
EPDCs play a critical role in coronary artery formation during embryonic heart 
development mainly by differentiating into vascular cells.26 To demonstrate the ability of 
EPDCs to differentiate, epicardial cells were cultured from hearts of ROSAmTmG;Wt1CreER 
mice at P0. Treatment with tamoxifen (200 nM) in the cultured ROSAmTmG;Wt1CreER 
EPDCs showed Cre activation resulting in GFP expression in 60-70% of Wt1+ EPDCs 
(Figure 4.9A). The Wt1+ EPDCs were also found to have differentiated into SMA+ cells 
(Figure 4.9B). So our next aim was to determine the lineage of Wt1 expressing cells in 
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Figure 4.7 Lineage tracing of Wt1+ cell derived EPDCs 5 days post-MI.  
(A) Experimental outline for genetic fate mapping in the adult heart using 
ROSAmTmG;Wt1CreER mice. (B) Representative images of GFP staining in the epicardium 
5 days post-MI. (C) Representative images of GFP staining of the infarct area 5 days 
post-MI. (D and E) Quantification of GFP+ cells in the epicardium (D) and infarcted 
myocardium (E). Significantly more Wt1+ cell derived EPDCs were found in the 
epicardium and infarct area in the Ad-hSCF treated compared to the Ad-LacZ group 5 
days post-MI. ACK2 treatment abolished the increase of GFP+ cells in the heart. (F) 
TGFβ mRNA expression determined by real-time RT-PCR. In vivo Ad-hSCF treatment 
in the myocardium induced significantly more TGFβ mRNA expression post-MI. This 
was abrogated by ACK2. Data are mean ± SEM, n=6. Two-way ANOVA followed by 
Bonferroni test: *P<0.05 vs Ad-LacZ. 
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Figure 4.8 Expression of hSCF protein in adenovirus treated hearts.  
Heart tissues from ROSAmTmG;Wt1CreER mice injected with Ad-hSCF or Ad-LacZ were 
subjected to western blot analysis. Expression of hSCF protein was observed only in Ad-
hSCF injected hearts. 
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Figure 4.9 In vitro lineage tracing of Wt1+ cell derived EPDCs.  
(A): Representative images of EPDCs from P0 ROSAmTmG;Wt1CreER  or ROSAmTmG mice 
treated with tamoxifen (200 nM). GFP+ cells (green) were observed only in EPDCs from 
the ROSAmTmG;Wt1CreER hearts. (B): Representative images of passage 1 EPDCs from 
ROSAmTmG;Wt1CreER hearts stained with GFP and SMA (nuclear: blue, SMA: red, GFP: 
green) 
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 the infarct area post-MI in ROSAmTmG;Wt1CreER mice after tamoxifen treatment. As 
shown in Figure 4.10A, some of the GFP+ cells in the infarct area were also positive for 
SMA, a marker for smooth muscle cells and myofibroblasts, indicating that the Wt1+ 
EPDCs differentiate into smooth muscle cells or myofibroblasts. Furthermore, treatment 
with Ad-hSCF induced significantly higher numbers of GFP+ and SMA+ cells (Figure 
4.10B and C). However, the percentage of SMA+ cells in relation to the total number of 
GFP+ cells (~34%) in the infarcted myocardium was similar between Ad-LacZ and Ad-
hSCF treated groups (Figure 4.10D), suggesting Ad-hSCF treatment does not affect 
EPDC differentiation. Additionally, no SMA+ cells from the Wt1+ cell lineage were 
detected in any vessels in the peri-infarct area. 
4.5 DISCUSSION 
 The present study demonstrates for the first time that cardiomyocyte-specific 
expression of membrane-associated hSCF promotes epicardial activation post-MI. The 
hSCF transgene expression increases epicardial Wt1+ EPDCs and arteriogenesis post-MI. 
These effects are specific to hSCF as they are abrogated upon treatment with DOX, 
which turns off hSCF expression. More importantly, through Wt1 lineage tracing, we 
showed that hSCF overexpression enhances EPDC activation and migration into the 
infarct area post-MI through the c-kit signaling pathway. Furthermore, hSCF stimulates 
EPDCs to express VEGF and bFGF, which are important growth factors in 
arteriogenesis. Our study suggests that hSCF overexpression enhances epicardial 
activation, EPDC production, and arteriogenesis post-MI. 
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Figure 4.10 Fate-mapping of Wt1+ cell derived EPDCs post-MI.  
(A) Representative images of GFP and SMA staining of Wt1-derived EPDCs in the 
infarct area. The GFP+ cells are also positive for SMA (arrows). (B) Quantification of the 
SMA+/GFP+ cells in the infarcted myocardium. The number of SMA+/GFP+ cells was 
higher in Ad-hSCF treated compared to the Ad-LacZ infarcted myocardium. (C) 
Quantification of the GFP+ cells in the infarcted myocardium. The number of GFP+ cells 
was increased with Ad-hSCF compared to Ad-LacZ treatment. (D) Ratio of SMA+/GFP+ 
cells. The ratio of SMA+/GFP+ cells was not significantly different between Ad-hSCF 
and Ad-LacZ treatment. Data are mean ± SEM, n=6. Unpaired student t test: *P<0.05 vs 
Ad-LacZ. 
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The adult epicardium can be re-activated and express Wt1 post-MI.29 In present 
study, epicardial activation as determined by Wt1 positivity was observed 3 days post-
MI, which is consistent with previous studies.29-31 Our novel finding is that 
overexpression of hSCF significantly enhanced the epicardial activation post-MI, and the 
response was abrogated by inhibiting c-kit receptor function, suggesting an important role 
of SCF/c-kit signaling in epicardial activation. TGFβ has been shown to promote EMT in 
both embryonic and adult EPDCs.32 A significant increase of TGFβ mRNA expression 
was found in the hSCF overexpressing myocardium post-MI and the effect was 
attenuated by DOX treatment to turn off hSCF expression or ACK2 treatment to inhibit 
c-kit receptor function. Furthermore, nuclear Smad2 phosphorylation was observed in 
epicardial Wt1+ cells, suggesting activation of TGFβ signaling in Wt1+ epicardial cells 
post-MI.  
The embryonic epicardium is active with Wt1+ expression and contributes to 
coronary artery formation.4,33 We therefore hypothesize that enhanced epicardial 
activation by cardiac specific overexpression of hSCF increases arteriogenesis post-MI. 
To test this hypothesis, myocardial arteriole density was determined. Our data showed 
that hSCF overexpression significantly increased arteriole density in the peri-infarct area, 
suggesting a potential contribution of epicardial activation to arteriogenesis post-MI. In 
order to further investigate the effect of SCF on EPDC activity, overexpression of hSCF 
was induced in cultured EPDCs. Our data showed that the ability of cultured EPDCs to 
proliferate and migrate was significantly enhanced by hSCF overexpression via c-kit 
signaling. Moreover, expression of VEGF-A and bFGF, two well-known pro-angiogenic 
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growth factors involved in arteriogenesis,34,35 was up-regulated through SCF/c-kit 
pathway suggesting an enhanced paracrine effect of EPDCs. 
In order to trace cell fate of the activated epicardium in vivo, a 
ROSAmTmG;Wt1CreER mouse was generated in which Cre recombinase expression is 
inducible by tamoxifen treatment, and Wt1 expression cells and their progeny will be 
EGFP+. Myocardial hSCF overexpression was achieved by intra-myocardial injection of 
adenoviral hSCF constructs. Consistent with what we found in the hSCF/tTA mice, 
overexpression of hSCF by adenoviral infection enhanced epicardial activation post-MI 
in ROSAmTmG;Wt1CreER mice as shown by a significantly higher number of EGFP+ 
epicardial cells. A hallmark of activated EPDCs is their ability to undergo EMT and 
migrate into the myocardium.17 Zhou et al. also investigated the migration of EPDCs 
using the same lineage tracing system. However, the EGFP+ EPDCs remained in the 
epicardial region and did not migrate into the myocardium.29 This is not surprising as 
their study was specifically designed to trace Wt1+ epicardial cells before the onset of 
MI. In the present study we used a tamoxifen treatment protocol to turn on Cre 
recombinase activity at the peak of epicardial Wt1 expression, and were able to see 
EGFP+ cells in the infarcted myocardium 5 days post-MI. More importantly, hSCF 
overexpression significantly increased the number of EGFP+ cells migrated into the 
myocardium. A significant increase of TGFβ mRNA expression was also observed post-
MI in the myocardium of Ad-hSCF treated ROSAmTmG;Wt1CreER mice. Furthermore, 
increases in EPDC migration and TGFβ expression were abrogated by inhibition of c-kit 
signaling. Together, these data show activation of SCF/c-kit signaling promotes EMT of 
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Wt1+ EPDCs and their migration into the infarcted myocardium via upregulation of 
TGFβ. 
Following EMT and migration into the myocardium during embryonic heart 
development, EPDCs differentiate into several cellular lineages including 
cardiomyocytes, endothelial cells, smooth muscle cells and interstitial fibroblasts.3,4,26 
Although the adult epicardium can be re-activated post-MI, cell fate of EPDCs remains to 
be determined. Through lineage tracing of Wt1+ EPDCs, we showed that the total number 
of EPDCs and their SMA+ derivatives were significantly increased by hSCF 
overexpression. However, their commitment to smooth muscle and/or myofibroblast 
lineages 5 days post-MI was not altered by hSCF overexpression (Figure. 4.10D). The 
SMA+ cell lineage was mainly found in the infarct area while arteriogenesis was 
predominantly in the peri-infarct area. The fact that not a single artery is derived from the 
EPDC lineage suggests that the increased arteriogenesis by hSCF overexpression is 
mainly due to paracrine effects. Of interest, lineage commitment of EPDCs post-MI may 
be partially modified. To this end, Smart et al. successfully induced 0.6% of Wt1+ EPDCs 
differentiation into structurally coupled cardiomyocytes using thymosin β4.30 However, 
this observation was not reproduced by Zhou et al.36 In the present study, we did not 
observe any effects of hSCF overexpression on cardiomyocyte generation from the 
EPDCs.  
In summary, the present study showed that cardiac specific hSCF overexpression 
promotes epicardial activation, EPDC production, growth factor expression and 
arteriogenesis post-MI. These effects may contribute to a significant improvement in 
cardiac function and survival in hSCF/tTA mice post-MI as demonstrated in Chapter 2. 
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Our study provides novel insight in EPDC activation post-MI and suggests that hSCF 
may have therapeutic potential in promoting cardiac repair post-MI.  
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5 CHAPTER 5 
5.1 SUMMARY OF MAJOR FINDINGS 
The overall objective of this thesis was to investigate the regulatory role of M-
SCF in cardiac function and repair post-MI. Specifically, I studied the effects of M-SCF 
on cardioprotection and myocardial repair post-MI via regulating the activities of c-kit 
expressing stem cells in the heart. To achieve this goal, a novel cardiac specific hSCF 
overexpressing mouse was generated. Experimental approaches included in vitro cell 
culture and in vivo animal studies as well as the use of pharmacological inhibitors and 
adenoviral constructs.  
In Chapter 2, I investigated the effects of cardiac-specific overexpression of 
hSCF on cardiac function and survival post-MI in mice. I demonstrated for the first time 
that hSCF overexpression promoted animal survival 30 days post-MI, which is 
accompanied by a significant preservation of cardiac performance. The underlying 
protective mechanisms include increases in angiogenesis and decreases in myocardial 
apoptosis and cardiac remodeling in the transgenic mice compared to WT. Furthermore, 
increased c-kit+ stem/progenitor cell number post-MI were observed in the myocardium, 
which is associated with the beneficial outcomes. Interestingly, cells expressing EPC 
markers were found to differentiate into small vessels in hSCF overexpressing 
myocardium, which suggests that M-SCF contributes to vasculogenesis post-MI. When 
hSCF expression was turned off by DOX treatment, all the beneficial effects were 
abrogated. The data further support the notion that M-SCF is responsible for the 
myocardial protection observed in the hSCF overexpressing mice. The cardioprotective 
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effects of M-SCF were recently confirmed by Higuchi et al, using lentiviral infection to 
overexpress mouse M-SCF in the myocardium.1 They showed improved survival and 
cardiac performance in M-SCF overexpressing mice, which is consistent with our 
findings.  
Loss of functional cardiomyocytes and myocardial injury within a few hours after 
ischemia or I/R produce pathological changes in the heart which may ultimately lead to 
heart failure. Thus, in Chapter 3, I investigated the role of M-SCF in acute myocardial 
I/R injury and related signaling pathways. I demonstrated that cardiac-specific 
overexpression of hSCF reduces infarct size after acute I/R via inhibition of myocardial 
apoptosis. Among the signaling pathways involved in protecting cardiomyocytes from 
apoptosis after I/R, Akt has been found to play a critical role in our previous studies.2 In 
agreement with those observations, I further demonstrated that the PI3K/Akt/eNOS 
signaling pathway is responsible for the anti-apoptotic effect of hSCF overexpression in 
the heart after acute I/R. Although many studies have shown improvements in infarct size 
and myocardial function by enhancing circulating stem cell recruitment 3,4  and/or 
activation of endogenous CSCs,5 it remains unclear how such changes affect myocardial 
cell death within the first few hours after I/R. To this end, I provided novel evidence that 
the myocardial c-kit+ cell population was increased within 4 hours after I/R in the WT 
heart, while a further significant increase of c-kit+ cells was observed in mice with cardiac 
specific hSCF overexpression. The increase of c-kit+ cells was accompanied by higher 
levels of myocardial expression of HGF and IGF-1, both of which are cardioprotective 
growth factors well-recognized in anti-apoptotic signaling pathways.6-8 As expected, 
blockade of SCF/c-kit signaling abrogated the beneficial effects of hSCF overexpression 
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in acute I/R including lower infarct size, and higher protective growth factor expression 
and c-kit+ cell numbers. The subpopulations of c-kit+ cells were further determined by 
CD45 expression. The number of CD45-/c-kit+ CSCs was increased in response to acute 
I/R in peri- and non-infarct area while a further increase of these cells was observed in 
hSCF overexpressing hearts. Consistent with findings in Chapter 2, retention of 
circulating CD45+c-kit+ cells was also enhanced in hSCF overexpressing myocardium 
after acute I/R.  
Using adenoviral constructs to overexpress M-SCF in the heart, a recent study 
demonstrated that infarct size was decreased 2 weeks post-MI in mice.9 Increased 
myocardial c-kit+ cell population associated with M-SCF overexpression 1 week post-MI 
was also reported. Although the authors concluded that there was increased activation of 
endogenous CSCs in the myocardium treated with the M-SCF recombinant adenovirus 
post-MI, no clear markers were employed to distinguish circulating stem cells and CSCs.9  
Finally, I determined the effect of M-SCF on CSC activity in vitro by inducing 
M-SCF overexpression in isolated cardiac c-kit+ progenitor cells through adenoviral 
infection. Enhanced proliferation and HGF expression was found in M-SCF 
overexpressing CSCs. Therefore, my study provided the first direct evidence that 
endogenous CSCs are activated shortly after I/R and M-SCF can enhance their activation. 
Taken together, in Chapter 3, I demonstrated that cardiac specific overexpression of 
hSCF reduces infarct size and myocardial apoptosis via the PI3K/Akt/eNOS signaling 
pathway through the enhanced paracrine effects from the retained circulating c-kit+ stem 
cells and activation of endogenous CSCs. 
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In Chapter 4, I investigated the role of M-SCF on EPDCs in cardiac repair post-
MI. Embryonic EPDCs are vascular and myocyte progenitors that regulate vascular cell 
and cardiomyocyte generation by direct differentiation as well as paracrine effects.10,11 
The therapeutic potential of adult EPDCs is implied by recent studies showing that these 
cells can be reactivated post-MI 12 and that transplantation of human EPDCs into the 
infarcted myocardium improves cardiac function post-MI.13 Limana et al.12 reported that 
a subset of EPDCs post-MI were c-kit+ and could give rise to both myocardial and 
vascular cells. Thus, I hypothesized that cardiac specific overexpression of hSCF 
promotes epicardial activation post-MI. Using in vitro EPDCs in cultures and in vivo 
lineage tracing models, I demonstrated for the first time the effects of M-SCF on EPDC 
activation and arteriogenesis post-MI. In comparison to results observed with WT mice, 
cardiac specific M-SCF overexpression promoted EPDC activation and arteriogenesis 
post-MI. I further investigated the fate of Wt1+ EPDCs post-MI using a lineage tracing 
model. Overexpression of M-SCF by adenoviral infection enhanced Wt1+ EPDC 
activation and migration to the infarcted myocardium. In agreement with observations 
from other studies,14,15 one third of the Wt1+ EPDCs which had migrated into the 
infarcted myocardium and differentiated into SMA positive cells. However, no 
integration of Wt1+ EPDCs in arterioles in the peri-infarct area was found, suggesting 
that the increased arteriogenesis in the peri-infarct area of hSCF overexpressing 
myocardium may result from paracrine effects of EPDCs instead of direct differentiation. 
This is supported by a recent study demonstrating the importance of paracrine factors in 
EPDCs-induced cardioprotection.14 Moreover, in vitro, M-SCF overexpression enhanced 
EPDC proliferation, migration and pro-arteriogenesis growth factor release, which was 
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abolished by blocking SCF/c-kit signaling. Additionally, although EPDCs contribute to 
myocardiogenesis during embryogenesis, no cardiomyocyte regeneration from Wt1+ 
EPDCs in the adult heart was observed in my study, as well as by others.14  
In summary, I have demonstrated the beneficial effects of  cardiac specific M-
SCF overexpression in regulating activities of circulating c-kit+ stem/progenitor cells, 
CSCs and EPDCs, which leads to cardioprotection in acute I/R injury and chronic MI. 
My studies may provide important information for developing novel therapeutic 
strategies for the treatment of MI. Overexpression of myocardial M-SCF not only 
enhances endogenous protection and repair mechanisms but may also increase the 
efficacy of stem cell therapy post-MI. A summary of the findings is depicted in Figure 
5.1. 
 
5.2 STUDY LIMITATIONS  
5.2.1 Inducible Cardiac-specific hSCF Overexpressing Transgenic Mice  
In a report published in 1996, Majumdar et al described a line of transgenic 
C3H/HeJ mice with the membrane associated hSCF gene under the control of the hPGK 
promoter.16 The homozygous hSCF transgenic mice displayed a coat color deficiency as 
well as abnormal thymocyte development. The phenotypes were claimed to result from 
hSCF interference with c-kit signaling and altered endogenous mouse M-SCF expression. 
However, no in vivo data or direct evidence of hSCF inhibiting mouse SCF/c-kit 
signaling in melanocytes was shown. Although the relatively low binding affinity  
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Figure 5.1 Summarized cellular mechanisms by which M-SCF improves cardiac 
function and animal survival post-MI.  
The interaction of SCF with c-kit receptors improves cardiac repair post-MI by enhanced 
EPC retention and activation of CSCs and EPDCs, leading to increased 
neovascularization, and decreased myocardial apoptosis and cardiac hypertrophy mainly 
through paracrine effects.  
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(Kd>700 nM) of soluble hSCF to mouse c-kit expressed on Chinese hamster ovary cells 
was demonstrated a decade ago,17 no study has been performed to demonstrate the 
binding affinity of membrane-associated isoform of hSCF to mouse c-kit receptor. 
Despite the difference in binding affinity between species, soluble hSCF has been shown 
to be able to induce biological effects on mouse c-kit+ cells.16 Moreover, the normal 
fertile and hematopoietic system in the hSCF transgenic mice suggested that the hSCF 
could interact with mouse c-kit and induce biological function signaling.16  
In this thesis, inducible cardiac specific hSCF overexpressing mice were created 
by expressing the hSCF gene under the α-MHC promoter. MHC is the major component 
of the heart’s contractile apparatus encoded by the α- or β-MHC gene.18 In the mouse, 
during gestation, β-MHC is expressed in ventricles but silenced after birth,19 while α-
MHC starts to be expressed in ventricles after birth and through adulthood. By using the 
α-MHC promoter to induce the expression of hSCF transgene, we successfully generated 
cardiac specific hSCF overexpressing mice without affecting embryonic development. 
Thus, in our cardiac specific hSCF overexpressing mice, coat color, heart morphology 
and cardiac function are normal. Furthermore, in our hSCF overexpressing mice, the 
expression of endogenous mouse SCF was not affected under either sham or MI 
conditions. However, I did find that after overexpression of hSCF, the expression of 
mouse soluble SCF was upregulated in cultured neonatal cardiomyocytes, which likely 
contributed to enhanced EPDC transwell migration in vitro.  
5.2.2 Use of Mouse Model to Simulate Human Disease Conditions 
This thesis mainly utilized in vivo experimental mouse models to simulate human 
heart disease. The use of mouse models to simulate human disease is necessary in the 
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evaluation of basic pathophysiological changes and potential therapeutics. Advantages 
for using animal models include: the control of experimental conditions, genetic 
manipulations (knockout or overexpression), and the ease access to tissues, which is 
difficult or impossible in humans. Furthermore, over 99% of all mouse genes have human 
homologues.20 Thus, insights gained from genetically modified mice may be applied to 
develop therapeutics for human disease. In this thesis, a novel inducible cardiac specific 
hSCF overexpressing mouse was generated. The reasons we chose the human M-SCF 
gene to create the transgenic mice are as follows. First, the effects of human M-SCF on 
MI can be studied. Second, it is easier to verify transgene expression in the heart. Third, 
human M-SCF remains more membrane-bound than mouse M-SCF.21 Last, although the 
binding affinity of human SCF to mouse c-kit is not the same as mouse SCF, their 
biological effects are similar as demonstrated in previous studies.22 
In Chapters 2 and 4, I used a mouse MI model in which the left main coronary 
artery was permanently ligated and evaluations were performed at 3-5 and 30 days post-
MI to simulate early and late stages of human heart failure, respectively. Similar to 
observations in human MI, our mouse model of MI showed myocardial infarct formation, 
cardiac dysfunction, and increased mortality. By utilizing inducible overexpression of the 
hSCF gene in the heart, I was able to study the effects of M-SCF post-MI and elucidate 
the related mechanisms. In Chapter 3, a murine model of cardiac I/R originally 
described by Michael et al.23 was performed by ligation of the left main coronary artery 
to generate ischemia for 45 minutes followed by untying the artery to return blood flow 
for 3 hours. In humans, myocardial I/R is associated with significant cell death resulting 
in formation of infarction.24 In my study, myocardial I/R in mice were also associated 
211 
 
with increased myocardial apoptosis and infarct formation. However, the direct effects of 
M-SCF in the human heart remain to be studied in patients with MI.  
5.2.3 Contributions of Soluble SCF  
Although in my thesis, the SCF overexpressed in mice is a membrane-associated 
isoform (Figure 5.2), the existence of a secondary proteinase cleavage site may also lead 
to a slow release of soluble SCF, which may possibly contribute to the cardioprotection 
observed in the M-SCF overexpression mice post-MI. It is well-known that soluble SCF 
enhances stem cell mobilization from the bone marrow to the peripheral circulation. 
However, we were not able to detect any soluble human SCF in the serum of hSCF 
overexpressing mice (Figure 5.3). Moreover, a previous study using lentivirus to 
overexpress mouse M-SCF in the heart did not show any changes in CD34+ or c-kit+ cells 
in the peripheral circulation post-MI.1 Consistent with these data, a recent report using 
adenovirus to overexpress M-SCF in the myocardium also failed to showed any changes 
in c-kit+ cells in the bone marrow and peripheral blood post-MI.9 These studies suggest 
that the beneficial effects of myocardial M-SCF overexpression post-MI in vivo are not 
likely due to the release of S-SCF into the circulation from M-SCF.  
5.2.4 Use of Pharmacological Inhibitors and Neutralizing Antibody to Delineate 
Signaling Pathways 
In Chapter 3 of this thesis, I used the PI3K inhibitor LY294002 to blocking the 
PI3K/Akt signaling pathway. LY294002 is a morpholine derivative of quercetin. It can 
selectively and completely abolish PI3K activity with an IC50 of 1.4 µM.25 Inhibition of 
other downstream signaling pathways of PI3K is an obvious limitation of using 
LY294002. Additionally, Akt can be activated independent of PI3K. In my studies  
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Figure 5.2 Expression of hSCF in WT and hSCF/tTA mice.  
Fluorescent images showed the expression of hSCF protein. Blue: nuclei; red: hSCF. The 
hSCF protein was observed on the plasma membrane of cardiomyocytes from hSCF/tTA 
mice. DOX treatment turned off the expression of hSCF in hSCF/tTA mice. 
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Figure 5.3 Soluble hSCF is not detectable in the serum of WT and hSCF/tTA mice.  
Expression of hSCF protein was detected by western analysis. Expression of soluble 
hSCF was not detectable in the serum of WT and hSCF/tTA mice. Hearts from 
hSCF/tTA mice were used as positive control. Each lane represents a sample from a 
separate animal. 
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however, LY294002 inhibited more than 50% of myocardial Akt activation, 
demonstrating its efficiency in blocking Akt signaling.  
Crizotinib, a small molecule inhibitor of HGF receptor, c-Met, was also used in 
Chapter 3. It has been shown to potently inhibit c-Met phosphorylation (IC50=11nM), 
HGF/c-Met signaling and exhibit an antitumor effect in tumor models at well-tolerated 
doses in vivo.26 One of the limitations of using crizotinib is that it can also inhibit 
anaplastic lymphoma kinase and c-ros oncogene 1.  
In Chapters 3 and 4, c-kit neutralizing antibody ACK2 was employed to block 
SCF/c-kit signaling. ACK2 reacts with c-kit and inhibits the binding of SCF to c-kit. 
Therefore, this antibody serves as a specific inhibitor to c-kit. The dose I chose for in vivo 
injection is equivalent to the studies performed by Dr. Nishikawa and colleagues who 
initially produced this antibody.27   
5.3 SUGGESTIONS FOR FUTURE RESEARCH 
The novelty of this thesis is the demonstration that myocardial M-SCF 
overexpression protects the heart from MI and I/R injury by regulating the activity of 
several types of stem/progenitor cells. However, how M-SCF regulates those 
stem/progenitor cells and whether M-SCF may induce myocardial regeneration warrant 
further investigation.   
In Chapter 2, I observed that M-SCF overexpression increased the retention and 
differentiation of cells expressing EPC markers. The ability of M-SCF to enhance EPC 
adhesion was also reported by Dentelli et al.28 who showed that M-SCF expression in 
human microvascular endothelial cells induced during inflammation was necessary for c-
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kit+ EPC recruitment via the interaction of M-SCF and c-kit. Soluble SCF has been 
established to directly enhance the neovascularization potential of EPCs in vivo and in 
vitro.29 However, how M-SCF directly regulates EPC activity is still unclear. The 
regenerated small vessels from EPCs in the infarcted myocardium provide evidence that 
M-SCF may directly affect the vasculogenic potential of EPCs. It will be interesting to 
further investigate the role of M-SCF in EPC activity under physiological and different 
pathological conditions such as inflammation or hyperglycemia. 
In Chapter 3, the observation that the population of CSCs is higher in the hSCF 
overexpressing myocardium under basal conditions provides a reasonable rationale to 
further study the effects of M-SCF on changes in the CSC population over time from 
birth to adulthood. Myocardial c-kit+ cells have been shown to be dramatically reduced 7 
days after birth and remain scarce through the adulthood.30 Future studies are necessary 
to address the following issues. For example, does cardiac specific M-SCF 
overexpression maintain a higher CSC pool after birth and in the aging myocardium? 
How does M-SCF regulate the activities of CSCs under basal conditions and in response 
to ischemic injuries? Additionally, the neonatal mouse heart has been shown to have a 
transient regeneration capacity after partial LV apex resection (~15% of LV 
myocardium).31 By lineage mapping of α-MHC the authors concluded that the 
regenerated myocardium results mainly from the proliferation of the preexisting 
myocytes. In my opinion, this conclusion remains questionable based on 2 reasons. First, 
the half-life of tamoxifen is about 5-7 days, which gives at least a 5-day window to label 
all cells expressing α-MHC including the differentiated CSCs. Second, the physiological 
changes of α-MHC expression in cardiomyocytes 1 week after birth 19 make lineage 
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mapping of α-MHC a sub-optimal method to study the cell source of neonatal myocardial 
regeneration. Instead, an inducible c-kit lineage tracing system may provide more 
accurate information on the regeneration potency of CSCs. Thus, the role of M-SCF in 
neonatal CSC proliferation and differentiation, and also whether M-SCF reserves some of 
the regenerative potential of the heart after birth, would be interesting topics for further 
investigations.    
The effects of M-SCF on adult EPDC activation, proliferation and migration were 
demonstrated in Chapter 4. However, whether M-SCF affects embryonic EPDC activity 
is not known. During embryonic heart development, EPDCs contribute to the formation 
of coronary arteries. Our recent studies have revealed that eNOS deficiency impairs 
embryonic coronary artery development via decreased activity of EPDCs.32 Malformation 
of coronary arteries renders the adult heart more susceptible to ischemic injury during 
increased demand for oxygen in conditions such as intense exercise. Consistent with this 
notion, patients with hypoplastic coronary artery disease die from sudden death mainly 
due to acute MI.33,34 In Chapter 3, I also showed that eNOS is a downstream target of 
SCF/c-kit activation via PI3K/Akt signaling. Thus, the hypothesis that M-SCF may 
regulate EPDC activity and promote embryonic coronary artery development can be 
tested in future studies. Additionally, Chapter 4 showed that M-SCF increases the 
number of activated EPDCs which migrate into the myocardium and differentiate into 
SMA+ cells post-MI. During the early infarct healing process, SMA+ myofibroblasts have 
beneficial effects against cardiac rupture through the production of collagen and 
extracellular matrix to form an infarct scar.35 The contribution of EPDCs to the formation 
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of a strong granulated scar to avoid cardiac rupture post-MI and the role of M-SCF in this 
process would be another interesting area of future research. 
Finally, activities and function of stem/progenitor cells have been shown to be 
impaired in other pathological conditions in the heart such as diabetic cardiomyopathy 36 
and hypertension-induced cardiac hypertrophy.37 Whether cardiac-specific 
overexpression of M-SCF enhances cardiac stem/progenitor cell activity and improves 
myocardial function and animal survival in these disease conditions remains to be 
investigated. 
5.4 CLINICAL APPLICATION 
Over the past decade, there has been advancement in transduction efficiency and 
safety of viral vectors for cardiovascular gene therapy.38 This powerful technology has 
opened a window for applying newly discovered potential therapeutic targets to treat 
IHD. I have shown the dramatic effects of M-SCF in cardiac repair post-MI using 
transgenic mice. How to translate these observations in animal models into clinical 
practice remains challenging but presumably feasible. Successful delivery of the M-SCF 
gene into the myocardium via adenovirus in mice has been achieved in my study as well 
as by others.9 Sun et al showed that sustained expression of myocardial M-SCF 
expression was achieved for a full year after the delivery of the M-SCF gene via 
lentivirus in neonatal mice.39 Moreover, the beneficial effects of M-SCF post-MI were 
also observed in aged mice.39 Given the growing evidence of M-SCF cardioprotective 
effects in animal models, there is ostensible therapeutic value for M-SCF gene therapy in 
patients with IHD.  
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5.5 CONCLUSIONS 
This thesis provides the first evidence that cardiac specific overexpression of M-
SCF offers cardiac protection and improves cardiac repair post-MI. While further 
investigation is required to determine the therapeutic potential of M-SCF in the treatment 
of IHD, it is clear that cardiac-specific overexpression of M-SCF is beneficial post-MI. 
Furthermore, this work has provided valuable insight into the mechanisms by which M-
SCF increases retention and differentiation of EPCs (Chapter 2), enhances proliferation 
and paracrine effects of CSCs (Chapter 3) and promotes activation, proliferation and 
migration of EPDCs (Chapter 4). Overall my doctoral research has broadened our 
understanding of M-SCF in the regulation of stem/progenitor cell activity and cardiac 
function in MI, and may contribute to the development of therapeutics for the treatment 
of IHD. 
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